

# Schizophrenia Bulletin Index—2003–04

## Author Index

### A

- Adami, Helene M.** *See* Avila, Matthew T.
- Adès, Jean.** *See* Dubertret, Caroline
- Aguilar, M. Carmen.** *See* Gurpegui, Manuel
- Aharon, Nelson.** *See* Silver, Henry
- Akabaliev, Valentin H.** *See* Sivkov, Stefan T.
- Alphs, Larry; Anand, Ravi; Islam, M. Zahur; Meltzer, Herbert Y.; Kane, John; Krishnan, Ranga; Green, Alan I.; Potkin, Steven; Chouinard, Guy; Lindenmayer, Jean-Pierre; and Kerwin, Rob.**  
The International Suicide Prevention Trial (InterSePT): Rationale and design of a trial comparing the relative ability of clozapine and olanzapine to reduce suicidal behavior in schizophrenia and schizoaffective patients, 30(3):577–586, 2004
- Alvir, Jose Ma. J.** *See* Strous, Rael D.
- Amador, Xavier F., and Fitzpatrick, Michael.**  
Science to services: Consumers need “real-world” science, 29(1):133–137, 2003
- an der Heiden, Wolfram.** *See* Häfner, Heinz
- Anand, Ravi.** *See* Alphs, Larry
- Angermeyer, Matthias C., and Matschinger, Herbert.** *See also* Jungbauer, Johannes  
The stereotype of schizophrenia and its impact on discrimination

against people with schizophrenia: Results from a representative survey in Germany, 30(4):1049–1061, 2004

**Appels, Melanie C.M.; Sitskoorn, Margriet M.; Vollema, Meinte G.; and Kahn, René S.**

Elevated levels of schizotypal features in parents of patients with a family history of schizophrenia spectrum disorders, 30(4):781–790, 2004

**Auerbach, Judith G.** *See* Hans, Sydney L.

**Auther, Andrea M.; Lencz, Todd; Smith, Christopher W.; Bowie, Christopher R.; and Cornblatt, Barbara A.** *See also* Cornblatt, Barbara A.; Lencz, Todd

Overview of the First Annual Workshop on the Schizophrenia Prodrome, 29(4):625–631, 2003

**Autonell, J.** *See* Ochoa, S.

**Avila, Matthew T.; Adami, Helene M.; McMahon, Robert P.; and Thaker, Gunvant K.**

Using neurophysiological markers of genetic risk to define the boundaries of the schizophrenia spectrum phenotype, 29(2):299–309, 2003

**Avila, Matthew T.; Sherr, Jay; Valentine, Leanne E.; Blaxton, Teresa A.; and Thaker, Gunvant K.**  
Neurodevelopmental interactions conferring risk for schizophrenia: A study of dermatoglyphic markers in patients and relatives, 29(3):595–605, 2003

**Avramopoulos, Dimitrios.** *See* Stefanis, Nicholas C.

### B

**Bak, Maarten; Myin-Germeys, Inez; Hanssen, Manon; Bijl, Rob; Vollebergh, Wilma; Delespaul, Philippe; and van Os, Jim.**

When does experience of psychosis result in a need for care? A prospective general population study, 29(2):349–358, 2003

**Baldwin, David S.** *See* Sinclair, Julia M.A.

**Balzuweit, Sabine.** *See* Marneros, Andreas

**Barbui, Corrado.** *See* Garattini, Livio

**Barch, Deanna M.** *See* Melinder, Meredith R.D.

**Barshtein, Gregory; Ponizovsky, Alexander M.; Nechamkin, Yakov; Ritsner, Michael; Yedgar, Saul; and Bergelson, Lev D.**

Aggregability of red blood cells of schizophrenia patients with negative syndrome is selectively enhanced, 30(4):913–922, 2004

**Basile, Vincenzo S.** *See* Petronis, Arturas

**Baumgart, Frank.** *See* Northoff, Georg

**Bearden, Carrie E.** *See* Cannon, Tyrone D.

**Bebout, Richard R.** *See* McHugo, Gregory J.

**Becker, Deborah.** *See* McHugo, Gregory J.

**Becker, Thomas.** *See* Ruggeri, Mirella; van Wijngaarden, Bob  
**Bell, Morris D.** *See* Lysaker, Paul H.  
**Bellack, Alan S.** *See* Twamley, Elizabeth W.  
**Berenbaum, Howard; Valera, Eve M.; and Kerns, John G.**  
 Psychological trauma and schizotypal symptoms, 29(1):143–152, 2003  
**Beresford, Carol.** *See* Ross, Randal G.  
**Bergelson, Lev D.** *See* Barshtein, Gregory  
**Berger, Gregor.** *See* Wood, Stephen J.  
**Berger, Mathias.** *See* Janssen, Birgit  
**Bernardo, Miquel.** *See* Rami, Lorena  
**Berns, Stefanie M.** *See* Jaeger, Judith  
**Biggs, Melanie.** *See* Miller, Alexander L.  
**Bijl, Rob.** *See* Bak, Maarten  
**Bilbe, Graeme.** *See* Carpenter, William T., Jr.  
**Bilder, Robert M.** *See* Keefe, Richard S.E.  
**Bingham, C. Raymond.** *See* Valenstein, Marcia  
**Binneman, Brendan.** *See* Das, Mri-gendra  
**Bischoff, Serge.** *See* Carpenter, William T., Jr.  
**Bisoffi, Giulia.** *See* Ruggeri, Mirella  
**Blaxton, Teresa A.** *See* Avila, Matthew T.  
**Blöink, Raffaella.** *See* Marneros, Andreas  
**Blow, Frederic C.** *See* Valenstein, Marcia  
**Blyler, Crystal R.**  
 Commentary: Service system perspectives on early intervention research, 29(4):867–875, 2003  
**Boeker, Heinz.** *See* Northoff, Georg  
**Boerescu, Daniela.** *See* Lehman, Anthony F.  
**Bogerts, Bernhard.** *See* Northoff, Georg  
**Boget, Teresa.** *See* Rami, Lorena  
**Bono, Adele.** *See* Garattini, Livio

**Bonomo, Giuseppe.** *See* Garattini, Livio  
**Bow-Thomas, Christine.** *See* Miller, Alexander L.  
**Bowie, Christopher R.** *See* Auther, Andrea M.  
**Brar, Jaspreet Singh.** *See* Strassnig, Martin  
**Breiling, James.** *See* Heinssen, Robert K.  
**Brekke, John S.** *See* Kee, Kimmy S.  
**Brody, Janet L.** *See* Roberts, Laura Weiss  
**Bromet, Evelyn J.** *See* Mojtabai, Ramin  
**Bryson, Gary J.** *See* Lysaker, Paul H.  
**Buchanan, Robert W.** *See* Kreyenbuhl, Julie; Lehman, Anthony F.  
**Butterfield, Marian I.** *See* Mueser, Kim T.  
**Byerly, Matthew J.** *See* Stroup, T. Scott

## C

**Cadenhead, Kristen.** *See* Miller, Tandy J.  
**Calkins, Monica E.; Curtis, Clayton E.; Grove, William M.; and Iacono, William G.**  
 Multiple dimensions of schizotypy in first degree biological relatives of schizophrenia patients, 30(2):317–325, 2004  
**Candela, Steven F.** *See* Manschreck, Theo C.  
**Canive, Jose M.** *See* Stroup, T. Scott  
**Cannon, Tyrone D.; van Erp, Theo G.M.; Bearden, Carrie E.; Loewy, Rachel; Thompson, Paul; Toga, Arthur W.; Huttunen, Matti O.; Keshavan, Matcheri S.; Seidman, Larry J.; and Tsuang, Ming T.** *See also* Cornblatt, Barbara A.  
 Early and late neurodevelopmental influences in the prodrome to schizophrenia: Contributions of genes, environment, and their interactions, 29(4):653–669, 2003  
**Carmody, Thomas.** *See* Miller, Alexander L.

**Carpenter, William T., Jr.; Koenig, James I.; Bilbe, Graeme; and Bischoff, Serge.**  
 At issue: A model for academic/industry collaboration, 30(4):992–1004, 2004  
**Cather, Corrine.** *See* Penn, David L.  
**Caviness, Verne S.** *See* Seidman, Larry J.  
**Chakos, Miranda.** *See* Strous, Rael D.  
**Chamberlin, Cliff.** *See* Penn, David L.  
**Chang, Bernard P., and Lenzenweger, Mark F.**  
 Investigating graphesthesia task performance in the biological relatives of schizophrenia patients, 30(2):327–334, 2004  
**Chant, David.** *See* Davies, Geoffrey  
**Chervenak, Frank A.** *See* Coverdale, John H.  
**Chiles, John.** *See* Miller, Alexander L.  
**Chiles, Judith.** *See* Miller, Alexander L.  
**Chouinard, Guy.** *See* Alphas, Larry  
**Chouinard, Sylvie; Poulin, Julie; Stip, Emmanuel; and Godbout, Roger.**  
 Sleep in untreated patients with schizophrenia: A meta-analysis, 30(4):957–967, 2004  
**Cleghorn, Stephen.** *See* McHugo, Gregory J.  
**Clemente, Rosa.** *See* Garattini, Livio  
**Cochrane, Jeanette.** *See* Durbin, Janet  
**Cohen, Alex S., and Docherty, Nancy M.**  
 Deficit versus negative syndrome in schizophrenia: Prediction of attentional impairment, 30(4):827–835, 2004  
**Coleman, Rae Lynnette.**  
 Home sweet home, 29(2):399–400, 2003  
**Collins, Pamela Y.** *See* Link, Bruce G.  
**Colpe, Lisa J.** *See* Heinssen, Robert K.

**Combs, Dennis R., and Gouvier, Wm. Drew.**

The role of attention in affect perception: An examination of Mirsky's four factor model of attention in chronic schizophrenia, 30(4):727-738, 2004

**Compagnon, Nina.** *See* Ross, Randal G.

**Conklin, Heather M., and Iacono, William G.**

At issue: Assessment of schizophrenia: Getting closer to the cause, 29(3):405-411, 2003

**Conley, Robert R.** *See* Kelly, Deanna L.

**Copeland, Laurel A.** *See* Valenstein, Marcia

**Copolov, David L.; Mackinnon, Andrew; and Trauer, Tom.**

Correlates of the affective impact of auditory hallucinations in psychotic disorders, 30(1):163-171, 2004

**Corcoran, Cheryl; Walker, Elaine; Huot, Rebecca; Mittal, Vijay; Tessner, Kevin; Kestler, Lisa; and Malaspina, Dolores.**

The stress cascade and schizophrenia: Etiology and onset, 29(4):671-692, 2003

**Cornago, Dante.** *See* Garattini, Livio

**Cornblatt, Barbara A.; Heinssen, Robert K.; Cannon, Tyrone D.; and Lencz, Todd.**

Editors' introduction: New frontiers in prodromal research, 29(4):621-623, 2003

**Cornblatt, Barbara A.; Lencz, Todd; Smith, Christopher W.; Correll, Christoph U.; Auther, Andrea M.; and Nakayama, Emilie.** *See also* Auther, Andrea M.; Lencz, Todd; Maier, Wolfgang

The schizophrenia prodrome revisited: A neurodevelopmental perspective, 29(4):633-651, 2003

**Correll, Christoph U.** *See* Cornblatt, Barbara A.; Kane, John M.; Lencz, Todd

**Corrigan, Patrick W., and Watson, Amy C.** *See also* Watson, Amy C.

At Issue: Stop the stigma: Call mental illness a brain disease, 30(3):477-479, 2004

**Corrigan, Patrick W.; Markowitz, Fred E.; and Watson, Amy C.**

Structural levels of mental illness stigma and discrimination, 30(3):481-491, 2004

**Corrigan, Patrick W.; Salzer, Mark; Ralph, Ruth O.; Sangster, Yvette; and Keck, Lorraine.**

Examining the factor structure of the Recovery Assessment Scale, 30(4):1035-1041, 2004

**Covell, Nancy H.; Weissman, Ellen M.; and Essock, Susan M.** *See also* Essock, Susan M.; Jackson, Carlos T.

Weight gain with clozapine compared to first generation antipsychotic medications, 30(2):229-240, 2004

**Covelli, Giampiero.** *See* Garattini, Livio

**Coverdale, John H.; McCullough, Laurence B.; and Chervenak, Frank A.**

Assisted and surrogate decision making for pregnant patients who have schizophrenia, 30(3):659-664, 2004

**Crismon, M. Lynn.** *See* Miller, Alexander L.

**Crown, William H.** *See* Lehman, Anthony F.

**Cuesta, Manuel J.** *See* Peralta, Victor

**Curtis, Clayton E.** *See* Calkins, Monica

**Cuthbert, Bruce N.** *See* Heinssen, Robert K.

**Czobor, Pál.** *See* Jaeger, Judith

## D

**Dagerman, Karen.** *See* Schneider, Lon S.

**Dama, Alfredo.** *See* Garattini, Livio

**Danos, Peter.** *See* Northoff, Georg

**Das, Mrigendra; Kumari, Veena; Soni, William; Ettinger, Ulrich;**

**Binneman, Brendan; Hughes, Catherine; Mehrotra, Ravi; and Sharma, Tonmoy.**

Neurological soft signs and their relationship to cognitive and clinical efficacy of atypical antipsychotics in schizophrenia, 30(2):241-253, 2004

**Davies, Geoffrey; Welham, Joy; Chant, David; Torrey, E. Fuller; and McGrath, John.**

A systematic review and meta-analysis of Northern Hemisphere season of birth studies in schizophrenia, 29(3):587-593, 2003

**Davis, C.E.** *See* Davis, Sonia M.

**Davis, Sonia M.; Koch, Gary G.; Davis, C.E.; and LaVange, Lisa M.** *See also* Schneider, Lon S.

Statistical approaches to effectiveness measurement and outcome-driven re-randomizations in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) studies, 29(1):73-80, 2003

**Day, Samantha.** *See* Peters, Emmanuelle

**de Haan, Lieuwe; Linszen, Don H.; Lenior, Marie E.; de Win, Evelyne Doderlein; and Gorsira, Rob.**

Duration of untreated psychosis and outcome of schizophrenia: Delay in intensive psychosocial treatment versus delay in treatment with antipsychotic medication, 29(2):341-348, 2003

**de Leon, Jose.** *See* Gurpegui, Manuel

**de Win, Evelyne Doderlein.** *See* de Haan, Lieuwe

**Delahanty, Janine.** *See* Lehman, Anthony F.

**Delepaup, Philippe.** *See* Bak, Maarten

**Desmond, Patricia.** *See* Wood, Stephen J.

**Diaz, Francisco J.** *See* Gurpegui, Manuel

**Dickerson, Faith B.** *See* Lehman, Anthony F.

**Dietrich, Sandra.** *See* Jungbauer, Johannes

**Dixon, Lisa B.** See Lehman, Anthony F.

**Docherty, Nancy M.** See Cohen, Alex S.

**Dolan-Sewell, Regina.** See Heinssen, Robert K.

**Domino, Marisa Elena; Frank, Richard G.; and Rosenheck, Robert.**

The diffusion of new antipsychotic medications and formulary policy, 29(1):95-104, 2003

**Doreleijers, Theo A.H.** See Vreugdenhil, Coby

**Doyle, Jefferson.** See Rosenheck, Robert A.

**Drake, Robert E.** See Essock, Susan M.; McHugo, Gregory J.

**Dubertret, Caroline; Adès, Jean; and Gorwood, Philip.**

Clinical and etiopathogenic specificities of the French concept of psychose hallucinatoire chronique compared to schizophrenia, 30(1):173-184, 2004

**Durbin, Janet; Goering, Paula; Cochrane, Jeanette; Macfarlane, Dianne; and Sheldon, Tess.**

Needs-based planning for persons with schizophrenia residing in board-and-care homes, 30(1):123-132, 2004

## E

**Ekerwald, Hedvig.** See Stålberg, Gabriella

**Elbogen, Eric B.** See Swanson, Jeffrey W.

**EPSILON Study Group.** See Rugeri, Mirella; van Wijngaarden, Bob

**Eronen, Markku.** See Holli, Matti M.

**Essock, Susan M.; Covell, Nancy H.; and Weissman, Ellen M.** See also Covell, Nancy H.; Jackson, Carlos T.; Mueser, Kim T.

Inside the black box: The importance of monitoring treatment implementation, 30(3):613-615, 2004

**Essock, Susan M.; Drake, Robert E.; Frank, Richard G.; and McGuire, Thomas G.**

Randomized controlled trials in evidence-based mental health care: Getting the right answer to the right question, 29(1):115-123, 2003

**Estroff, Sue E.; Penn, David L.; and Toporek, Julie R.**

From stigma to discrimination: An analysis of community efforts to reduce the negative consequences of having a psychiatric disorder and label, 30(3):493-509, 2004

**Etter, Jean-François.** See Etter, Manuela

**Etter, Manuela, and Etter, Jean-François.**

Alcohol consumption and the CAGE test in outpatients with schizophrenia or schizoaffective disorder and in the general population, 30(4):947-956, 2004

**Etter, Manuela; Mohr, Sylvia; Garin, Claire; and Etter, Jean-François.**

Stages of change in smokers with schizophrenia or schizoaffective disorder and in the general population, 30(2):459-468, 2004

**Ettinger, Ulrich.** See Das, Mrigendra  
**Evdokimidis, Ioannis.** See Stefanis, Nicholas C.

**Even, Sandrine.** See Fortier, Pierre

## F

**Falkai, Peter.** See Seidman, Larry J.

**Fallin, M. Danielle.** See McGrath, John A.

**Faraone, Stephen V.** See Seidman, Larry J.

**Farley, Gordon.** See Ross, Randal G.

**Fenton, Wayne S.** See Otey, Emeline; Watson, Amy C.

**Ferrer, José.** See Rami, Lorena

**Fiorillo, Andrea.** See Garattini, Livio

**Fischer, Ellen P.** See Lehman, Anthony F.

**Fitzpatrick, Michael.** See Amador, Xavier F.

**5 Site Health and Risk Study Research Committee.** See Mueser, Kim T.

**Foley, Kathy.** See Rothbard, Aileen B.

**Fontana, Alan.** See Rosenheck, Robert A.

**Fortier, Pierre; Mottard, Jean-Pierre; Trudel, Gilles; and Even, Sandrine.**

Study of sexuality-related characteristics in young adults with schizophrenia treated with novel neuroleptics and in a comparison group of young adults, 29(3):559-572, 2003

**Fox, Valerie.**

First person account: Schizophrenia and motherhood, 30(4):763-765, 2004

**Frangou, Sophia.** See Reeder, Clare

**Frank, Richard G.** See Domino, Marisa Elena; Essock, Susan M.

**Furlan, Pier Maria.** See Garattini, Livio

## G

**Gad, Gilad.** See Strous, Rael D.

**Gabel, Wolfgang.** See Janssen, Birgit

**Ganguli, Rohan.** See Strassnig, Martin

**Ganju, Vijay.**

Implementation of evidence-based practices in state mental health systems: Implications for research and effectiveness studies, 29(1):125-131, 2003

**Garattini, Livio; Barbui, Corrado; Clemente, Rosa; Cornago, Dante; and Parazzini, Fabio, on behalf of the Study Group SCORE.**

Direct costs of schizophrenia and related disorders in Italian community mental health services: A multicenter, prospective 1-year followup study, 30(2):295-302, 2004

**Gardner, April L.** See Watson, Amy C.



**Garety, Philippa.** *See* Peters, Emmanuelle

**Garin, Claire.** *See* Etter, Manuela

**Garrett, Michael, and Silva, Raul.**

Auditory hallucinations, source monitoring, and the belief that "voices" are real, 29(3):445-457, 2003

**Gatta, Patrizia.** *See* Garattini, Livio

**Geddes, John.**

Generating evidence to inform policy and practice: The example of the second generation "atypical" antipsychotics, 29(1):105-114, 2003

**Gibson, P. Joseph.** *See* Mojtabai, Ramin

**Gillon, Leah.** *See* Valenstein, Marcia

**Gilvary, Catherine M.** *See* Mata, Ignacio

**Gladsjo, Julie Akiko; McAdams, Lou Ann; Palmer, Barton W.; Moore, David J.; Jeste, Dilip V.; and Heaton, Robert K.**

A six-factor model of cognition in schizophrenia and related psychotic disorders: Relationships with clinical symptoms and functional capacity, 30(4):739-754, 2004

**Glick, Ira D.** *See* Stroup, T. Scott

**Gloege, Andrew.** *See* Penn, David L.

**Godbout, Roger.** *See* Chouinard, Sylvie

**Goering, Paula.** *See* Durbin, Janet

**Gold, James M.** *See* Keefe, Richard S.E.

**Goldberg, Richard.** *See* Lehman, Anthony F.

**Goldman, Morris B., and Mitchell, Colin P.**

What is the functional significance of hippocampal pathology in schizophrenia?, 30(2):367-392, 2004

**Goldstein, Jill M.** *See* Seidman, Larry J.

**Goodman, Lisa A.** *See* Mueser, Kim T.

**Gorsira, Rob.** *See* de Haan, Lieuwe

**Gorwood, Philip.** *See* Dubertret, Caroline

**Gottesman, Irving I.** *See* Petronis, Arturas

**Gouvier, Wm. Drew.** *See* Combs, Dennis R.

**Grace, Anthony A.** *See* Thompson, Judy L.

**Green, Alan I.** *See* Alphas, Larry

**Green, Michael F.** *See* Kee, Kimmy S.; Keefe, Richard S.E.; Wiedl, Karl H.

**Green-Paden, Lisa D.** *See* Lehman, Anthony F.

**Greig, Tamasine C.** *See* Lysaker, Paul H.

**Grove, William M.** *See* Calkins, Monica

**Gurpegui, Manuel; Aguilar, M. Carmen; Martínez-Ortega, José M.; Diaz, Francisco J.; and de Leon, Jose.**

Caffeine intake in outpatients with schizophrenia, 30(4):935-945, 2004

**Gutman, Yaakov.** *See* Yogeve, Herzel

## H

**Haak, David C.** *See* Swartz, Marvin S.

**Haas, Gretchen.** *See* Keshavan, Matcheri S.

**Hadar, Uri.** *See* Yogeve, Herzel

**Häfner, Heinz; Maurer, Kurt; Löfner, Walter; an der Heiden, Wolfram; Hambrecht, Martin; and Schultze-Lutter, Frauke.**

Modeling the early course of schizophrenia, 29(2):325-340, 2003

**Hagino, Hirofumi.** *See* Nakamura, Kazuo

**Hall, Laura Lee.**

Half-full but nearly empty: Implications of the Schizophrenia PORT updated treatment recommendations, 30(3):619-621, 2004

**Hambrecht, Martin.** *See* Häfner, Heinz

**Hans, Sydney L.; Auerbach, Judith G.; Styr, Benedict; and Marcus, Joseph.**

Offspring of parents with schizophrenia: Mental disorders during childhood and adolescence, 30(2):303-315, 2004

**Hanssen, Manon.** *See* Bak, Maarten; Hardy-Baylé, Marie-Christine; Sarfati, Yves; and Passerieux, Christine.

The cognitive basis of disorganization symptomatology in schizophrenia and its clinical correlates: Toward a pathogenetic approach to disorganization, 29(3):459-471, 2003

**Haring, Annette.** *See* Marneros, Andreas

**Haro, J.M.** *See* Ochoa, S.

**Harris, Maxine.** *See* McHugo, Gregory J.

**Harrow, Martin; Herbener, Ellen S.; Shanklin, Anne; Jobe, Thomas H.; Rattenbury, Francine; and Kaplan, Kalman J.** *See also* Herbener, Ellen S.

Followup of psychotic outpatients: Dimensions of delusions and work functioning in schizophrenia, 30(1):147-161, 2004

**Harvey, Philip D.** *See also* Keefe, Richard S.E.

Commentary: Chickens and eggs; carts and horses: An outsider's perspective on the study of the early stages and potential prevention of psychosis and schizophrenia, 29(4):845-849, 2003

**Hayes, Robyn Lynette, and O'Grady, Bethany Maree.**

Do people with schizophrenia comprehend what they read?, 29(3):499-507, 2003

**Heaton, Robert K.** *See* Gladsjo, Julie Akiko

**Heila, Hannele.** *See* Sakinofsky, Isaac

**Heinlein, Shari.** *See* Ross, Randal G.

**Heinssen, Robert K.; Cuthbert, Bruce N.; Breiling, James; Colpe, Lisa J.; and Dolan-Sewell, Regina.** *See also* Cornblatt, Barbara A.

Overcoming barriers to research in early serious mental illness: Issues for future collaboration, 29(4):737-745, 2003

**Heinzel, Alexander.** *See* Northoff, Georg

**Hell, Daniel.** *See* Schuepbach, Daniel

**Herbener, Ellen S., and Harrow, Martin.** *See also* Harrow, Martin  
Are negative symptoms associated with functioning deficits in both schizophrenia and nonschizophrenia patients? A 10-year longitudinal analysis, 30(4): 813–825, 2004

**Herring, Gloria.** *See* McHugo, Gregory J.

**Hijman, Ron; Pol, Hilleke E. Hulshoff; Sitskoorn, Margriet M.; and Kahn, René S.**

Global intellectual impairment does not accelerate with age in patients with schizophrenia: A cross-sectional analysis, 29(3):509–517, 2003

**Hill, S. Kristian.** *See* Schuepbach, Daniel

**Hirose, Shigehiro.**

The causes of underdiagnosing akathisia, 29(3):547–558, 2003

**Hodgins, Sheila.** *See* Moran, Paul  
**Hogan, Michael F.**

Updated Schizophrenia PORT treatment recommendations, 30(3):623–625, 2004

**Holi, Matti M.; Eronen, Markku; Toivonen, Kari; Toivonen, Päivi; Marttunen, Mauri; and Naukkarinen, Hannu.**

Left prefrontal repetitive transcranial magnetic stimulation in schizophrenia, 30(2):429–434, 2004

**Horton, Nicholas J.** *See* Seidman, Larry J.

**Hughes, Catherine.** *See* Das, Mri-gendra

**Hultman, Christina M.** *See* Stålberg, Gabriella

**Huot, Rebecca.** *See* Corcoran, Cheryl

**Huttunen, Matti O.** *See* Cannon, Tyrone D.

## I

**Iacono, William G.** *See* Calkins, Monica; Conklin, Heather M.

**Islam, M. Zahur.** *See* Alphs, Larry  
**Ismail, M. Saleem.** *See* Schneider, Lon S.

## J

**Jackson, Carlos T.; Covell, Nancy H.; and Essock, Susan M.**

Differential effectiveness of clozapine for patients nonresponsive to or intolerant of first generation antipsychotic medications, 30(2):219–227, 2004

**Jaeger, Judith; Berns, Stefanie M.; and Czobor, Pál.**

The Multidimensional Scale of Independent Functioning: A new instrument for measuring functional disability in psychiatric populations, 29(1):153–167, 2003

**Janssen, Birgit; Weinmann, Stefan; Berger, Mathias; and Gaebel, Wolfgang.**

Validation of polypharmacy process measures in inpatient schizophrenia care, 30(4): 1023–1033, 2004

**Jenner, Jack A.; Nienhuis, Fokko J.; Wiersma, Durk; and van de Willige, Gerard.**

Hallucination focused integrative treatment: A randomized controlled trial, 30(1):133–145, 2004

**Jennings, Nancy A.** *See* Stout, Patricia A.

**Jeste, Dilip V.** *See* Gladsjo, Julie Akiko; Twamley, Elizabeth W.

**Jobe, Thomas H.** *See* Harrow, Martin

**Johnstone, Bryan M.** *See* Lehman, Anthony F.

**Jones, Peter B.** *See* Mata, Ignacio

**Joseph, Stephen.** *See* Peters, Emmanuelle

**Joyal, Christian C.** *See* Putkonen, Anu

**Jungbauer, Johannes; Wittmund, Bettina; Dietrich, Sandra; and Angermeyer, Matthias C.**

The disregarded caregivers: Subjective burden in spouses of

schizophrenia patients, 30(3): 665–675, 2004

**Junginger, John, and McGuire, Lynanne.**

Psychotic motivation and the paradox of current research on serious mental illness and rates of violence, 30(1):21–30, 2004

## K

**Kahn, René S.** *See* Appels, Melanie C.M.; Hijman, Ron

**Kan, Peixiang.** *See* Petronis, Arturas  
**Kane, John M.** *See also* Alphs, Larry

PORT recommendations, 30(3): 605–607, 2004

**Kane, John M.; Krystal, John; and Correll, Christoph U.**

Treatment models and designs for intervention research during the psychotic prodrome, 29(4): 747–756, 2003

**Kaplan, Alla.** *See* Silver, Henry

**Kaplan, Kalman J.** *See* Harrow, Martin

**Kashner, T. Michael.** *See* Miller, Alexander L.

**Kato, Tadafumi.** *See* Watanabe, Akira

**Kaulisch, Thomas.** *See* Northoff, Georg

**Kawasaki, Yasuhiro.** *See* Nakamura, Kazue

**Keck, Lorraine.** *See* Corrigan, Patrick W.

**Kee, Kimmy S.; Green, Michael F.; Mintz, Jim; and Brekke, John S.**

Is emotion processing a predictor of functional outcome in schizophrenia?, 29(3):487–497, 2003

**Keefe, Richard S.E.; Mohs, Richard C.; Bilder, Robert M.; Harvey, Philip D.; Green, Michael F.; Meltzer, Herbert Y.; Gold, James M.; and Sano, Mary.**

Neurocognitive assessment in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project schizophrenia trial: Development, methodol-

- ogy, and rationale, 29(1):45–55, 2003
- Kelly, Deanna L., and Conley, Robert R.**  
Sexuality and schizophrenia: A review, 30(4):767–779, 2004
- Kennedy, James L.** *See* Petronis, Arturas
- Kerns, John G.** *See* Berenbaum, Howard
- Kerwin, Rob.** *See* Alphas, Larry
- Keshavan, Matcheri S.; Haas, Gretchen; Miewald, Jean; Montrose, Debra M.; Reddy, Ravinder; Schooler, Nina R.; and Sweeney, John A.** *See also* Cannon, Tyrone D.; Reddy, Ravinder D.; Schuepbach, Daniel; Seidman, Larry J.  
Prolonged untreated illness duration from prodromal onset predicts outcome in first episode psychoses, 29(4):757–769, 2003
- Kestler, Lisa.** *See* Corcoran, Cheryl
- King, Elizabeth A.** *See* Sinclair, Julia M.A.
- Knapp, Martin; Mangalore, Roshni; and Simon, Judit.** *See also* Ruggeri, Mirella; van Wijngaarden, Bob  
The global costs of schizophrenia, 30(2):279–293, 2004
- Knudsen, Helle Charlotte.** *See* Ruggeri, Mirella; van Wijngaarden, Bob
- Koch, Gary G.** *See* Davis, Sonia M.
- Koenig, James I.** *See* Carpenter, William T., Jr.
- Koeter, Maarten.** *See* van Wijngaarden, Bob
- Kopelowicz, Alex; Zarate, Roberto; Smith, Veronica Gonzalez; Mintz, Jim; and Liberman, Robert Paul.**  
Disease management in Latinos with schizophrenia: A family-assisted, skills training approach, 29(2):211–227, 2003
- Kotilainen, Irma.** *See* Putkonen, Anu
- Kötter, Rolf.** *See* Northoff, Georg
- Kreyenbuhl, Julie; Zito, Julie M.; Buchanan, Robert W.; Soeken, Karen L.; and Lehman, Anthony F.** *See also* Lehman, Anthony F.  
Racial disparity in the pharmacological management of schizophrenia, 29(2):183–193, 2003
- Krishnan, Ranga.** *See* Alphas, Larry; Sakinofsky, Isaac
- Krystal, John.** *See* Kane, John M.
- Kumari, Veena.** *See* Das, Mrigendra
- Kuno, Eri.** *See* Rothbard, Aileen B.
- Kurachi, Masayoshi.** *See* Nakamura, Kazue
- Kurokawa, Kenzo.** *See* Nakamura, Kazue
- ## L
- Lamb, Theodore A.** *See* Watson, Amy C.
- Laneri, Roberto.** *See* Garattini, Livio
- Lasalvia, Antonio.** *See* Ruggeri, Mirella; van Wijngaarden, Bob
- Lasseter, Virginia K.** *See* McGrath, John A.
- LaVange, Lisa M.** *See* Davis, Sonia M.
- Lavelle, Janet.** *See* Mojtabai, Ramin
- Lebowitz, Barry D.; Vitiello, Benedetto; and Norquist, Grayson S.**  
Approaches to multisite clinical trials: The National Institute of Mental Health perspective, 29(1):7–13, 2003
- Leese, Morven.** *See* van Wijngaarden, Bob
- Lehman, Anthony F.; Fischer, Ellen P.; Postrado, Leticia; Delahanty, Janine; Johnstone, Bryan M.; Russo, Patricia A.; and Crown, William H.** *See also* Kreyenbuhl, Julie  
The Schizophrenia Care and Assessment Program Health Questionnaire (SCAP-HQ): An instrument to assess outcomes of schizophrenia care, 29(2):247–256, 2003
- Lehman, Anthony F.; Kreyenbuhl, Julie; Buchanan, Robert W.; Dickerson, Faith B.; Dixon, Lisa B.; Goldberg, Richard; Green, Paden, Lisa D.; Tenhula, Wendy N.; Boerescu, Daniela; Tek, Cenk; Sandson, Neil; and Steinwachs, Donald M.**  
The Schizophrenia Patient Outcomes Research Team (PORT): Updated treatment recommendations 2003, 30(2):193–217, 2004
- Lencz, Todd; Smith, Christopher W.; Auther, Andrea M.; Correll, Christoph U.; and Cornblatt, Barbara A.** *See also* Auther, Andrea M.; Cornblatt, Barbara A.  
The assessment of “prodromal schizophrenia”: Unresolved issues and future directions, 29(4):717–728, 2003
- Lenior, Marie E.** *See* de Haan, Lieuwe
- Lenzenweger, Mark F.** *See* Chang, Bernard P.
- Leonard, Sherry.** *See* Yao, Jeffrey K.
- Leslie, Douglas L., and Rosenheck, Robert A.** *See also* Rosenheck, Robert A.  
Adherence of schizophrenia pharmacotherapy to published treatment recommendations: Patient, facility, and provider predictors, 30(3):649–658, 2004
- Leung, Jin Pang.** *See* Shum, David
- Lewine, Rich.**  
At issue: Sex and gender in schizophrenia, 30(4):755–762, 2004
- Lewis, Shôn W.** *See* Mata, Ignacio
- Liang, Kung-Yee.** *See* McGrath, John A.
- Liberman, Robert Paul.** *See* Kopelowicz, Alex
- Lieberman, Jeffrey A., and Stroup, T. Scott.** *See also* Stroup, T. Scott; Strous, Rael D.  
Guest editors’ introduction: What can large pragmatic clinical trials do for public mental health care?, 29(1):1–6, 2003
- Lindenmayer, Jean-Pierre.** *See* Alphas, Larry
- Link, Bruce G.; Yang, Lawrence H.; Phelan, Jo C.; and Collins, Pamela Y.**

- Measuring mental-illness stigma, 30(3):511-541, 2004
- Linszen, Don H.** *See* de Haan, Lieuwe
- Lo Monaco, Emanuele.** *See* Garattini, Livio
- Loewy, Rachel.** *See* Cannon, Tyrone D.
- Löffler, Walter.** *See* Häfner, Heinz
- Luchins, Daniel J.**  
At issue: Will the term brain disease reduce stigma and promote parity for mental illnesses?, 30(4):1043-1048, 2004
- Lysaker, Paul H.; Bryson, Gary J.; Marks, Kriscinda; Greig, Tamara C.; and Bell, Morris D.**  
Coping style in schizophrenia: Associations with neurocognitive deficits and personality, 30(1):113-121, 2004

## M

- Macfarlane, Dianne.** *See* Durbin, Janet
- Mackinnon, Andrew.** *See* Copolov, David L.
- Maher, Brendan A.** *See* Manschreck, Theo C.
- Maier, Wolfgang; Cornblatt, Barbara A.; and Merikangas, Kathleen R.**  
Transition to schizophrenia and related disorders: Toward a taxonomy of risk, 29(4):693-701, 2003
- Makris, Nikos.** *See* Seidman, Larry J.
- Malaspina, Dolores.** *See* Corcoran, Cheryl; Mojtabai, Ramin
- Mangalore, Roshni.** *See* Knapp, Martin
- Manschreck, Theo C.; Maher, Brendan A.; and Candela, Steven F.**  
Earlier age of first diagnosis in schizophrenia is related to impaired motor control, 30(2):351-360, 2004
- Marcus, Joseph.** *See* Hans, Sydney L.
- Markowitz Fred E.** *See* Corrigan, Patrick W.
- Marks, Kriscinda.** *See* Lysaker, Paul H.
- Marneros, Andreas; Pillmann, Frank; Haring, Annette; Balzuweit, Sabine; and Blöink, Raffaella.**  
What is schizophrenic in acute and transient psychotic disorder?, 29(2):311-323, 2003
- Màrquez, M.** *See* Ochoa, S.
- Marra, Giuseppe.** *See* Garattini, Livio
- Martin, Bradley C.** *See* Miller, L. Stephen
- Martínez-Ortega, José M.** *See* Gurpegui, Manuel
- Marttunen, Mauri.** *See* Holi, Matti M.
- Mata, Ignacio; Gilvarry, Catherine M.; Jones, Peter B.; Lewis, Shôn W.; Murray, Robin M.; and Sham, Pak C.**  
Schizotypal personality traits in nonpsychotic relatives are associated with positive symptoms in psychotic probands, 29(2):273-283, 2003
- Matschinger, Herbert.** *See* Angermeyer, Matthias C.
- Matsui, Mie.** *See* Nakamura, Kazuo
- Maurer, Kurt.** *See* Häfner, Heinz
- McAdams, Lou Ann.** *See* Gladsjo, Julie Akiko
- McCarthy, John F.** *See* Valenstein, Marcia
- McCullough, Laurence B.** *See* Coverdale, John H.
- McEvoy, Joseph P.** *See* Stroup, T. Scott; Swartz, Marvin S.
- McFarlane, William.** *See* Miller, Tandy J.
- McGee, Mark F.** *See* Stroup, T. Scott
- McGlashan, Thomas H.** *See also* Miller, Tandy J.  
Commentary: Progress, issues, and implications of prodromal research: An inside view, 29(4):851-858, 2003
- McGorry, Patrick D.; Yung, Alison R.; and Phillips, Lisa J.** *See also* Wood, Stephen J.  
The "close-in" or ultra high-risk model: A safe and effective strategy for research and clinical intervention in prepsychotic mental disorder, 29(4):771-790, 2003
- McGrath, John A.; Nestadt, Gerald; Liang, Kung-Yee; Lasseter, Virginia K.; Wolyniec, Paula S.; Fallin, M. Danielle; and Pulver, Ann E.**  
Five latent factors underlying schizophrenia: Analysis and relationship to illnesses in relatives, 30(4):855-873, 2004
- McGrath, John J.** *See* Davies, Geoffrey; Welham, Joy L.
- McGuire, Lynanne.** *See* Junginger, John
- McGuire, Thomas G.** *See* Essock, Susan M.
- McHugo, Gregory J.; Bebout, Richard R.; Harris, Maxine; Cleghorn, Stephen; Herring, Gloria; Xie, Haiyi; Becker, Deborah; and Drake, Robert E.**  
A randomized controlled trial of integrated *versus* parallel housing services for homeless adults with severe mental illness, 30(4):969-982, 2004
- McMahon, Robert P.** *See* Avila, Matthew T.
- McManus, Dennis.** *See* Schneider, Lon S.
- McNulty, James P.**  
Commentary: Mental illness, society, stigma, and research, 30(3):573-575, 2004
- Mehrotra, Ravi.** *See* Das, Mrigendra
- Melinder, Meredith R.D., and Barch, Deanna M.**  
The influence of a working memory load manipulation on language production in schizophrenia, 29(3):473-485, 2003
- Meltzer, Herbert Y.** *See* Alphas, Larry; Keefe, Richard S.E.
- Merikangas, Kathleen R.** *See* Maier, Wolfgang
- Miewald, Jean.** *See* Keshavan, Matcheri S.
- Miller, Alexander L.**  
PORT treatment recommendations, 30(3):601-604, 2004



**Miller, Alexander L.; Crismon, M. Lynn; Rush, A. John; Chiles, John; Kashner, T. Michael; Toprac, Marcia; Carmody, Thomas; Biggs, Melanie; Shores-Wilson, Kathy; Chiles, Judith; Witte, Brad; Bow-Thomas, Christine; Velligan, Dawn I.; Trivedi, Madhukar; Suppes, Trisha; and Shon, Steven.**

The Texas Medication Algorithm Project: Clinical results for schizophrenia, 30(3):627-647, 2004

**Miller, L. Stephen, and Martin, Bradley C.**

Current and future forecasts of service use and expenditures of Medicaid-eligible schizophrenia patients in the state of Georgia, 30(4):983-995, 2004

**Miller, Tandy J.; McGlashan, Thomas H.; Rosen, Joanna L.; Cadenhead, Kristen; Ventura, Joseph; McFarlane, William; Perkins, Diana O.; Pearson, Godfrey D.; and Woods, Scott W.**

Prodromal assessment with the Structured Interview for Prodromal Syndromes and the Scale of Prodromal Symptoms: Predictive validity, interrater reliability, and training to reliability, 29(4):703-715, 2003

**Mintz, Jim.** *See* Kee, Kimmy S.; Kopelowicz, Alex

**Mitchell, Colin P.** *See* Goldman, Morris B.

**Mittal, Vijay.** *See* Corcoran, Cheryl

**Mohr, Sylvia.** *See* Etter, Manuela

**Mohs, Richard C.** *See* Keefe, Richard S.E.

**Mojtabai, Ramin; Lavelle, Janet; Gibson, P. Joseph; and Bromet, Evelyn J.**

Atypical antipsychotics in first admission schizophrenia: Medication continuation and outcomes, 29(3):519-530, 2003

**Mojtabai, Ramin; Malaspina, Dolores; and Susser, Ezra.**

The concept of population prevention: Application to schizophrenia, 29(4):791-801, 2003

**Montrose, Debra M.** *See* Keshavan, Matcheri S.

**Moore, David J.** *See* Gladsjo, Julie Akiko

**Moran, Paul, and Hodgins, Sheilagh.**

The correlates of comorbid antisocial personality disorder in schizophrenia, 30(4):791-802, 2004

**Mottard, Jean-Pierre.** *See* Fortier, Pierre

**Mueser, Kim T.; Salyers, Michelle P.; Rosenberg, Stanley D.; Goodman, Lisa A.; Essock, Susan M.; Osher, Fred C.; Swartz, Marvin S.; Butterfield, Marian I.; and the 5 Site Health and Risk Study Research Committee.** *See also* Penn, David L.

Interpersonal trauma and posttraumatic stress disorder in patients with severe mental illness: Demographic, clinical, and health correlates, 30(1):45-57, 2004

**Mullee, Mark A.** *See* Sinclair, Julia M.A.

**Murray, Robin M.** *See* Mata, Ignacio

**Myin-Germeyns, Inez.** *See* Bak, Maarten

## N

**Nakamura, Kazue; Kawasaki, Yasuhiro; Suzuki, Michio; Hagino, Hirofumi; Kurokawa, Kenzo; Takahashi, Tsutomu; Niu, Lisha; Matsui, Mie; Seto, Hikaru; and Kurachi, Masayoshi.**

Multiple structural brain measures obtained by three-dimensional magnetic resonance imaging to distinguish between schizophrenia patients and normal subjects, 30(2):393-404, 2004

**Nakayama, Emilie.** *See* Cornblatt, Barbara A.

**Narendran, Rajesh.** *See* Valenti, Antoinette M.

**Naukkarinen, Hannu.** *See* Holi, Matti M.

**Nechamkin, Yakov.** *See* Barshtein, Gregory

**NEDES Group.** *See* Ochoa, S.

**Nestadt, Gerald.** *See* McGrath, John A.

**Neumann, Craig S., and Walker, Elaine F.**

Neuromotor functioning in adolescents with schizotypal personality disorder: Associations with symptoms and neurocognition, 29(2):285-298, 2003

**Newton, Elizabeth.** *See* Reeder, Clare

**Nguyen, Khanh.** *See* Roberts, Laura Weiss

**Nienhuis, Fokko J.** *See* Jenner, Jack A.

**Nieri, Jennifer M.** *See* Swartz, Marvin S.

**Niu, Lisha.** *See* Nakamura, Kazue

**Norquist, Grayson S.** *See* Lebowitz, Barry D.

**Northoff, Georg; Kötter, Rolf; Baumgart, Frank; Danos, Peter; Boeker, Heinz; Kaulisch, Thomas; Schlagenhauf, Florian; Walter, Henrik; Heinzel, Alexander; Witzel, Thomas; and Bogerts, Bernhard.**

Orbitofrontal cortical dysfunction in akinetic catatonia: A functional magnetic resonance imaging study during negative emotional stimulation, 30(2):405-427, 2004

**Ntzoufras, Ioannis.** *See* Stefanis, Nicholas C.

**Nuechterlein, Keith H.** *See* Wiedl, Karl H.

## O

**Ochoa, S.; Haro, J.M.; Autonell, J.; Pendàs, A.; Teba, F.; Màrquez, M.; and the NEDES Group.**

Met and unmet needs of schizophrenia patients in a Spanish sample, 29(2):201-210, 2003

**O'Grady, Bethany Maree.** *See* Hayes, Robyn Lynette



- Olin, Jason.** *See* Schneider, Lon S.  
**Ortwein-Swoboda, Gerhard.** *See* Stompe, Thomas  
**Osher, Fred C.** *See* Mueser, Kim T.  
**Otey, Emeline, and Fenton, Wayne S.** *See also* Watson, Amy C.  
 Editors' introduction: Building mental illness stigma research, 30(3):473-475, 2004  
**Otto, Michael W.** *See* Penn, David L.

## P

- Palmer, Barton W.** *See* Gladsjo, Julie Akiko  
**Pantelis, Christos.** *See* Seidman, Larry J.; Wood, Stephen J.  
**Parazzini, Fabio.** *See* Garattini, Livio  
**Parnas, Josef.** *See* Sass, Louis A.  
**Passerieux, Christine.** *See* Hardy-Baylé, Marie-Christine  
**Pastore, Gianfranco.** *See* Garattini, Livio  
**Paterson, Andrew D.** *See* Petronis, Arturas  
**Pearlson, Godfrey D.** *See* Miller, Tandy J.  
**Pendàs, A.** *See* Ochoa, S.  
**Penn, David L.; Chamberlin, Cliff; and Mueser, Kim T.** *See also* Estroff, Sue E.  
 The effects of a documentary film about schizophrenia on psychiatric stigma, 29(2):383-391, 2003  
**Penn, David L.; Mueser, Kim T.; Tarrier, Nick; Gloege, Andrew; Cather, Corrine; Serrano, Daniel; and Otto, Michael W.**  
 Supportive therapy for schizophrenia: Possible mechanisms and implications for adjunctive psychosocial treatments, 30(1):101-112, 2004  
**Peralta, Victor, and Cuesta, Manuel J.**  
 The nosology of psychotic disorders: A comparison among competing classification systems, 29(3):413-425, 2003  
**Perkins, Diana O.** *See* Miller, Tandy J.; Swartz, Marvin S.  
**Peters, Emmanuelle; Joseph, Stephen; Day, Samantha; and Garety, Philippa.**  
 Measuring delusional ideation: The 21-item Peters et al. Delusions Inventory (PDI), 30(4):1005-1022, 2004  
**Petronis, Arturas; Gottesman, Irving I.; Kan, Peixiang; Kennedy, James L.; Basile, Vincenzo S.; Paterson, Andrew D.; and Pependikyte, Violeta.**  
 Monozygotic twins exhibit numerous epigenetic differences: Clues to twin discordance?, 29(1):169-178, 2003  
**Pfeiffer, Eric.** *See* Schneider, Lon S.  
**Phelan, Jo C.** *See* Link, Bruce G.  
**Phillips, Lisa J.** *See* McGorry, Patrick D.; Wood, Stephen J.  
**Pillmann, Frank.** *See* Marneros, Andreas  
**Pogue-Geile, Michael F.** *See* Thompson, Judy L.  
**Pol, Hilleke E. Hulshoff.** *See* Hijman, Ron  
**Ponizovsky, Alexander M.** *See* Barshtein, Gregory  
**Pependikyte, Violeta.** *See* Petronis, Arturas  
**Portella, Maria J.** *See* Rami, Lorena  
**Postrado, Leticia.** *See* Lehman, Anthony F.  
**Potkin, Steven.** *See* Alphs, Larry  
**Poulin, Julie.** *See* Chouinard, Sylvie  
**Pristach, Cynthia A.** *See* Valenti, Antoinette M.  
**Pulver, Ann E.** *See* McGrath, John A.  
**Putkonen, Anu; Kotilainen, Irma; Joyal, Christian C.; and Tiitonen, Jari.**  
 Comorbid personality disorders and substance use disorders of mentally ill homicide offenders: A structured clinical study on dual and triple diagnoses, 30(1):59-72, 2004

## R

- Ralph, Ruth O.** *See* Corrigan, Patrick W.

- Rami, Lorena; Bernardo, Miquel; Valdes, Manuel; Boget, Teresa; Portella, Maria J.; Ferrer, Jose; and Salamero, Manel.**  
 Absence of additional cognitive impairment in schizophrenia patients during maintenance electroconvulsive therapy, 30(1):185-189, 2004  
**Rattenbury, Francine.** *See* Harrow, Martin  
**Reddy, Ravinder D.; Keshavan, Matcheri S.; and Yao, Jeffrey K.** *See also* Keshavan, Matcheri S.; Yao, Jeffrey K.  
 Reduced red blood cell membrane essential polyunsaturated fatty acids in first episode schizophrenia at neuroleptic-naïve baseline, 30(4):901-911, 2004  
**Reeder, Clare; Newton, Elizabeth; Frangou, Sophia; and Wykes, Til.**  
 Which executive skills should we target to affect social functioning and symptom change? A study of a cognitive remediation therapy program, 30(1):87-100, 2004  
**Ribar, Allyson Varina.**  
 First person account: Schizoaffective disorder and suicide, 30(3):677, 2004  
**Ritsner, Michael.** *See* Barshtein, Gregory  
**Roberts, Brian B.** *See* Roberts, Laura Weiss  
**Roberts, Laura Weiss; Warner, Teddy D.; Brody, Janet L.; Nguyen, Khanh; and Roberts, Brian B.**  
 What is ethically important in clinical research? A preliminary study of attitudes of 73 psychiatric faculty and residents, 29(3):607-613, 2003  
**Robinson, Delbert.** *See* Strous, Rael D.  
**Rosen, Joanna L.** *See* Miller, Tandy J.  
**Rosenberg, Stanley D.** *See* Mueser, Kim T.  
**Rosenheck, Robert A.; Doyle, Jefferson; Leslie, Douglas; and**

- Fontana, Alan.** *See also* Domino, Marisa Elena; Leslie, Douglas L.; Sernyak, Michael J.  
Changing environments and alternative perspectives in evaluating the cost-effectiveness of new antipsychotic drugs, 29(1):81-93, 2003
- Ross, Randal G.; Schaeffer, John; Compagnon, Nina; Heinlein, Shari; Beresford, Carol; and Farley, Gordon.**  
Creating school-age versions of semistructured interviews for the prodrome to schizophrenia: Lessons from case reviews, 29(4):729-735, 2003
- Rothbard, Aileen B.; Kuno, Eri; and Foley, Kathy.**  
Trends in the rate and type of antipsychotic medications prescribed to persons with schizophrenia, 29(3):531-540, 2003
- Ruggeri, Mirella; Lasalvia, Antonio; Bisoffi, Giulia; Thornicroft, Graham; Vázquez-Barquero, José Luis; Becker, Thomas; Knapp, Martin; Knudsen, Helle Charlotte; Schene, Aart; Tansella, Michele; and the EPSILON Study Group.**  
Satisfaction with mental health services among people with schizophrenia in five European sites: Results from the EPSILON study, 29(2):229-245, 2003
- Rush, A. John.** *See* Miller, Alexander L.
- Russo, Patricia A.** *See* Lehman, Anthony F.
- Ryan, J. Michael.** *See* Schneider, Lon S.
- S**
- Sakinofsky, Isaac; Heila, Hannele; and Krishnan, Ranga.**  
Estimating suicidality as outcome measure in clinical trials of suicide in schizophrenia, 30(3):587-598, 2004
- Salamero, Manel.** *See* Rami, Lorena
- Salomone, Giuseppina.** *See* Garatini, Livio
- Salsman, Susan A.**  
First person account: The best medicine, 29(3):615-616, 2003
- Salyers, Michelle P.** *See* Mueser, Kim T.
- Salzer, Mark.** *See* Corrigan, Patrick W.
- Sanders, Richard D.** *See* Schuepbach, Daniel
- Sandson, Neil.** *See* Lehman, Anthony F.
- Sangster, Yvette.** *See* Corrigan, Patrick W.
- Sano, Mary.** *See* Keefe, Richard S.E.
- Sarfati, Yves.** *See* Hardy-Baylé, Marie-Christine
- Sass, Louis A., and Parnas, Josef.**  
Schizophrenia, consciousness, and the self, 29(3):427-444, 2003
- Schaeffer, John.** *See* Ross, Randal G.
- Schanda, Hans.** *See* Stompe, Thomas
- Schene, Aart.** *See* Ruggeri, Mirella; van Wijngaarden, Bob
- Schlagenhauf, Florian.** *See* Northoff, Georg
- Schneider, Lon S.; Ismail, M. Saleem; Dagerman, Karen; Davis, Sonia; Olin, Jason; McManus, Dennis; Pfeiffer, Eric; Ryan, J. Michael; Sultzer, David L.; and Tariot, Pierre N.**  
Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE): Alzheimer's disease trial, 29(1):57-72, 2003
- Schooler, Nina R.** *See* Keshavan, Matcheri S.
- Schöttke, Hennning.** *See* Wiedl, Karl H.
- Schroeder, Cary.**  
First person account: My dream life, a normal life, 30(4):1063-1065, 2004
- Schuepbach, Daniel; Hill, S. Kristian; Sanders, Richard D.; Hell, Daniel; Keshavan, Matcheri S.; and Sweeney, John A.**  
Early treatment-induced improvement of negative symptoms predicts cognitive functioning in treatment-naïve first episode schizophrenia: A 2-year followup, 30(4):837-848, 2004
- Schultze-Lutter, Frauke.** *See* Häfner, Heinz
- Seidman, Larry J.; Pantelis, Christos; Keshavan, Matcheri S.; Faraone, Stephen V.; Goldstein, Jill M.; Horton, Nicholas J.; Makris, Nikos; Falkai, Peter; Caviness, Verne S.; and Tsuang, Ming T.** *See also* Cannon, Tyrone D.  
A review and new report of medial temporal lobe dysfunction as a vulnerability indicator for schizophrenia: A magnetic resonance imaging morphometric family study of the parahippocampal gyrus, 29(4):803-830, 2003
- Sernyak, Michael J., and Rosenheck, Robert A.**  
Risk adjustment in studies using administrative data, 29(2):267-271, 2003
- Serrano, Daniel.** *See* Penn, David L.
- Seto, Hikaru.** *See* Nakamura, Kazuo
- Sham, Pak C.** *See* Mata, Ignacio
- Shanklin, Anne.** *See* Harrow, Martin
- Sharma, Tonmoy.** *See* Das, Mrigendra
- Sheitman, Brian.** *See* Strous, Rael D.
- Sheldon, Tess.** *See* Durbin, Janet
- Sherr, Jay.** *See* Avila, Matthew T.
- Shon, Steven.** *See* Miller, Alexander L.
- Shores-Wilson, Kathy.** *See* Miller, Alexander L.
- Shum, David; Ungvari, Gabor S.; Tang, Wai-Kwong; and Leung, Jin Pang.**  
Performance of schizophrenia patients on time-, event-, and activity-based prospective memory tasks, 30(4):693-701, 2004
- Shumway, Martha.**  
Preference weights for cost-outcome analyses of schizophrenia treatments: Comparison of four stakeholder groups, 29(2):257-266, 2003
- Silva, Raul.** *See* Garrett, Michael

**Silver, Henry; Aharon, Nelson; and Kaplan, Alla.**

Add-on fluvoxamine improves primary negative symptoms: Evidence for specificity from response analysis of individual symptoms, 29(3):541-546, 2003

**Silverstein, Steven M., and Wilkness, Sandra.**

At issue: The future of cognitive rehabilitation of schizophrenia, 30(4):679-692, 2004

**Simon, Judith.** *See* Knapp, Martin

**Simpson, George M.** *See* Stroup, T. Scott

**Sinclair, Julia M.A.; Mullee, Mark A.; King, Elizabeth A.; and Baldwin, David S.**

Suicide in schizophrenia: The Wessex Recent Inpatient Suicide Study: A retrospective case-control study of 51 suicides, 30(4):803-811, 2004

**Sirota, Pinkhas.** *See* Yogeve, Herzel

**Sitskoorn, Margriet M.** *See* Appels, Melanie C.M.; Hijman, Ron

**Sivkov, Stefan T., and Akabaliev, Valentin H.**

Discriminating value of total minor physical anomaly score on the Waldrop Physical Anomaly Scale between schizophrenia patients and normal control subjects, 30(2):361-366, 2004

**Smith, Barbara B.**

First person account: Medicines are not enough, 29(1):139-142, 2003

**Smith, Christopher W.** *See* Auther, Andrea M.; Cornblatt, Barbara A.; Lencz, Todd

**Smith, Veronica Gonzalez.** *See* Kopelowicz, Alex

**Smyrnis, Nikolaos.** *See* Stefanis, Nicholas C.

**Soeken, Karen L.** *See* Kreyenbuhl, Julie

**Soni, William.** *See* Das, Mrigendra Stålberg, Gabriella; Ekerwald, Hedvig; and Hultman, Christina M.

At issue: Siblings of patients with schizophrenia: Sibling bond, coping patterns, and fear of pos-

sible schizophrenia heredity, 30(2):445-458, 2004

**Stavenger, Thomas.** *See* Valenstein, Marcia

**Stefanis, Costas N.** *See* Stefanis, Nicholas C.

**Stefanis, Nicholas C.; Smyrnis, Nikolaos; Avramopoulos, Dimitrios; Evdokimidis, Ioannis; Ntzoufras, Ioannis; and Stefanis, Costas N.**

Factorial composition of self-rated schizotypal traits among young males undergoing military training, 30(2):335-350, 2004

**Steinwachs, Donald M.** *See* Lehman, Anthony F.

**Stevens, Michael C.** *See* Stroup, T. Scott

**Stip, Emmanuel.** *See* Chouinard, Sylvie

**Stompe, Thomas; Ortwein-Swoboda, Gerhard; and Schanda, Hans.**

Schizophrenia, delusional symptoms, and violence: The threat/control-override concept reexamined, 30(1):31-44, 2004

**Stout, Patricia A.; Villegas, Jorge; and Jennings, Nancy A.**

Images of mental illness in the media: Identifying gaps in the research, 30(3):543-561, 2004

**Strassnig, Martin; Brar, Jaspreet Singh; and Ganguli, Rohan.**

Nutritional assessment of patients with schizophrenia: A preliminary study, 29(2):393-397, 2003

**Stroup, T. Scott; McEvoy, Joseph P.; and Lieberman, Jeffrey A.** *See also* Lieberman, Jeffrey A.; Swartz, Marvin S.

Revised PORT recommendations, 30(3):609-611, 2004

**Stroup, T. Scott; McEvoy, Joseph P.; Swartz, Marvin S.; Byerly, Matthew J.; Glick, Ira D.; Canive, Jose M.; McGee, Mark F.; Simpson, George M.; Stevens, Michael C.; and Lieberman, Jeffrey A.**

The National Institute of Mental Health Clinical Antipsychotic

Trials of Intervention Effectiveness (CATIE) project: Schizophrenia trial design and protocol development, 29(1):15-31, 2003

**Strous, Rael D.; Alvir, Jose Ma. J.; Robinson, Delbert; Gal, Gilad; Sheitman, Brian; Chakos, Miranda; and Lieberman, Jeffrey A.**

Premorbid functioning in schizophrenia: Relation to baseline symptoms, treatment response, and medication side effects, 30(2):265-278, 2004

**Study Group SCORE.** *See* Garattini, Livio

**Styr, Benedict.** *See* Hans, Sydney L.

**Sultzer, David L.** *See* Schneider, Lon S.

**Sundstrom, Eric.**

First person account: The clogs, 30(1):191-192

**Suppes, Trisha.** *See* Miller, Alexander L.

**Susser, Ezra.** *See* Mojtabai, Ramin

**Suzuki, Michio.** *See* Nakamura, Kazue

**Swanson, Jeffrey W.; Swartz, Marvin S.; and Elbogen, Eric B.**

Effectiveness of atypical antipsychotic medications in reducing violent behavior among persons with schizophrenia in community-based treatment, 30(1):3-20, 2004

**Swartz, Marvin S.; Perkins, Diana O.; Stroup, T. Scott; McEvoy, Joseph P.; Nieri, Jennifer M.; and Haak, David C.** *See also* Mueser, Kim T.; Stroup, T. Scott; Swanson, Jeffrey W.

Assessing clinical and functional outcomes in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial, 29(1):33-43, 2003

**Sweeney, John A.** *See* Keshavan, Matcheri S.; Schuepbach, Daniel

## T

**Takahashi, Tsutomu.** *See* Nakamura, Kazue

- Tang, Wai-Kwong.** *See* Shum, David
- Tansella, Michele.** *See* Ruggeri, Mirella; van Wijngaarden, Bob
- Tariot, Pierre N.** *See* Schneider, Lon S.
- Tarrier, Nick.** *See* Penn, David L.
- Teba, F.** *See* Ochoa, S.
- Tek, Cenk.** *See* Lehman, Anthony F.
- Tenhula, Wendy N.** *See* Lehman, Anthony F.
- Tessner, Kevin.** *See* Corcoran, Cheryl
- Thaker, Gunvant K.** *See* Avila, Matthew T.
- Thomis, Richard J.** *See* Welham, Joy L.
- Thompson, Judy L.; Pogue-Geile, Michael F.; and Grace, Anthony A.**  
Developmental pathology, dopamine, and stress: A model for the age of onset of schizophrenia symptoms, 30(4):875-900, 2004
- Thompson, Paul.** *See* Cannon, Tyrone D.
- Thornicroft, Graham.** *See* Ruggeri, Mirella; van Wijngaarden, Bob
- Tiihonen, Jari.** *See* Putkonen, Anu
- Toga, Arthur W.** *See* Cannon, Tyrone D.
- Toivonen, Kari.** *See* Holi, Matti M.
- Toivonen, Päivi.** *See* Holi, Matti M.
- Tolton, J.C.**  
First person account: How insight poetry helped me to overcome my illness, 30(2):469-472, 2004
- Toporek, Julie R.** *See* Estroff, Sue E.
- Toprac, Marcia.** *See* Miller, Alexander L.
- Torrey, E. Fuller.** *See also* Davies, Geoffrey  
PORT updated treatments recommendations, 30(3):617-618, 2004
- Trauer, Tom.** *See* Copolov, David L.
- Trivedi, Madhukar.** *See* Miller, Alexander L.
- Trudel, Gilles.** *See* Fortier, Pierre
- Tsuang, Ming T.** *See* Cannon, Tyrone D.; Seidman, Larry J.
- Twamley, Elizabeth W.; Jeste, Dilip V.; and Bellack, Alan S.**

A review of cognitive training in schizophrenia, 29(2):359-382, 2003

## U

**Ungvari, Gabor S.** *See* Shum, David

## V

- Valdes, Manuel.** *See* Rami, Lorena
- Valenstein, Marcia; Blow, Frederic C.; Copeland, Laurel A.; McCarthy, John F.; Zeber, John E.; Gillon, Leah; Bingham, C. Raymond; and Stavenger, Thomas.**  
Poor antipsychotic adherence among patients with schizophrenia: Medication and patient factors, 30(2):255-264, 2004
- Valenti, Antoinette M.; Narendran, Rajesh; and Pristach, Cynthia A.**  
Who are patients on conventional antipsychotics?, 29(2):195-199, 2003
- Valentine, Leanne E.** *See* Avila, Matthew T.
- Valera, Eve M.** *See* Berenbaum, Howard
- van de Willige, Gerard.** *See* Jenner, Jack A.
- van den Brink, Wim.** *See* Vreugdenhil, Coby
- van Erp, Theo G.M.** *See* Cannon, Tyrone D.
- van Os, Jim.** *See* Bak, Maarten
- van Wijngaarden, Bob; Schene, Aart; Koeter, Maarten; Becker, Thomas; Knapp, Martin; Knudsen, Helle Charlotte; Tansella, Michele; Thornicroft, Graham; Vázquez-Barquero, José-Luis; Lasalvia, Antonio; Leese, Morven; and the EPSILON study group.**  
People with schizophrenia in five countries: Conceptual similarities and intercultural differences in family caregiving, 29(3):573-586, 2003
- Vázquez-Barquero, José Luis.** *See* Ruggeri, Mirella; van Wijngaarden, Bob

- Velakoulis, Dennis.** *See* Wood, Stephen J.
- Velligan, Dawn I.** *See* Miller, Alexander L.
- Ventura, Joseph.** *See* Miller, Tandy J.
- Vermeiren, Robert.** *See* Vreugdenhil, Coby
- Villegas, Jorge.** *See* Stout, Patricia A.
- Viola, Marcello.** *See* Garattini, Livio
- Vitiello, Benedetto.** *See* Lebowitz, Barry D.
- Vollebergh, Wilma.** *See* Bak, Maarten
- Vollema, Meinte G.** *See* Appels, Melanie C.M.
- Vreugdenhil, Coby; Vermeiren, Robert; Wouters, Luuk F.J.M.; Doreleijers, Theo A.H.; and van den Brink, Wim.**  
Psychotic symptoms among male adolescent detainees in The Netherlands, 30(1):73-86, 2004

## W

- Walker, Elaine F.** *See* Corcoran, Cheryl; Neumann, Craig S.
- Walter, Henrik.** *See* Northoff, Georg
- Warner, Teddy D.** *See* Roberts, Laura Weiss
- Watanabe, Akira, and Kato, Tada-fumi.**  
Cerebrovascular response to cognitive tasks in patients with schizophrenia measured by near-infrared spectroscopy, 30(2):435-444, 2004
- Watson, Amy C.; Otey, Emeline; Westbrook, Anne L.; Gardner, April L.; Lamb, Theodore A.; Corrigan, Patrick W.; and Fenton, Wayne S.** *See also* Corrigan, Patrick W.  
Changing middle schoolers' attitudes about mental illness through education, 30(3):563-572, 2004
- Weiner, Susan K.**  
First person account: Living with the delusions and effects of

- schizophrenia, 29(4):877-879, 2003
- Weinmann, Stefan.** *See* Janssen, Birgit
- Weissman, Ellen M.** *See* Covell, Nancy H.; Essock, Susan M.
- Welham, Joy L.; Thomis, Richard J.; and McGrath, John J.** *See also* Davies, Geoffrey
- Age-at-first-registration for affective psychosis and schizophrenia, 30(4):849-853, 2004
- Westbrook, Anne L.** *See* Watson, Amy C.
- Wiedl, Karl H.; Schöttke, Hennning; Green, Michael F.; and Nuechterlein, Keith H.**
- Dynamic testing in schizophrenia: Does training change the construct validity of a test?, 30(4):703-711, 2004
- Wiersma, Durk.** *See* Jenner, Jack A.
- Wilkniss, Sandra.** *See* Silverstein, Steven M.
- Witte, Brad.** *See* Miller, Alexander L.
- Wittmund, Bettina.** *See* Jungbauer, Johannes

- Witzel, Thomas.** *See* Northoff, Georg
- Wolyniec, Paula S.** *See* McGrath, John A.
- Wood, Stephen J.; Berger, Gregor; Velakoulis, Dennis; Phillips, Lisa J.; McGorry, Patrick D.; Yung, Alison R.; Desmond, Patricia; and Pantelis, Christos.**
- Proton magnetic resonance spectroscopy in first episode psychosis and ultra high-risk individuals, 29(4):831-843, 2003
- Woods, Scott W.** *See* Miller, Tandy J.
- Wouters, Luuk F.J.M.** *See* Vreugdenhil, Coby
- Wykes, Til.** *See* Reeder, Clare

## X

- Xie, Haiyi.** *See* McHugo, Gregory J.

## Y

- Yang, Lawrence H.** *See* Link, Bruce G.
- Yao, Jeffrey K.; Leonard, Sherry; and Reddy, Ravinder D.** *See also* Reddy, Ravinder D.

- Increased nitric oxide radicals in postmortem brain from patients with schizophrenia, 30(4):923-934, 2004

- Yedgar, Saul.** *See* Barshtein, Gregory
- Yogev, Herzel; Sirota, Pinkhas; Gutman, Yaakov; and Hadar, Uri.**

- Latent inhibition and over-switching in schizophrenia, 30(4):713-726, 2004

- Yung, Alison R.** *See also* McGorry, Patrick D.; Wood, Stephen J.

- Commentary: The schizophrenia prodrome: A high-risk concept, 29(4):859-865, 2003

## Z

- Zarate, Roberto.** *See* Kopelowicz, Alex
- Zeber, John E.** *See* Valenstein, Marcia
- Zen, Laura.** *See* Garattini, Livio
- Zito, Julie M.** *See* Kreyenbuhl, Julie



## Subject Index

## A

**ABC study.** *See* Age, Beginning, Course study

**Academic/industry collaboration**

At issue: A model for academic/industry collaboration, 30(4):992–1004, 2004

**Acute and transient psychotic disorder**

What is schizophrenic in acute and transient psychotic disorder?, 29(2):311–323, 2003

**AD.** *See* Alzheimer's disease

**Administrative data**

Risk adjustment in studies using administrative data, 29(2):267–271, 2003

**Adolescents.** *See also* Children; Young adults

Changing middle schoolers' attitudes about mental illness through education, 30(3):563–572, 2004

Developmental pathology, dopamine, and stress: A model for the age of onset of schizophrenia symptoms, 30(4):875–900, 2004

Early and late neurodevelopmental influences in the prodrome to schizophrenia: Contributions of genes, environment, and their interactions, 29(4):653–669, 2003

Neuromotor functioning in adolescents with schizotypal personality disorder: Associations with symptoms and neurocognition, 29(2):285–298, 2003

Offspring of parents with schizophrenia: Mental disorders during childhood and adolescence, 30(2):303–315, 2004

Psychotic symptoms among male adolescent detainees in The Netherlands, 30(1):73–86, 2004

The schizophrenia prodrome revisited: A neurodevelopmental perspective, 29(4):633–651, 2003

**Adverse effects.** *See also* Extrapyramidal side effects; Side effects

Differential effectiveness of clozapine for patients nonresponsive to or intolerant of first generation antipsychotic medications, 30(2):219–227, 2004

PORT treatment recommendations, 30(3):601–604, 2004

Premorbid functioning in schizophrenia: Relation to baseline symptoms, treatment response, and medication side effects, 30(2):265–278, 2004

Who are patients on conventional antipsychotics?, 29(2):195–199, 2003

**Affect**

Correlates of the affective impact of auditory hallucinations in psychotic disorders, 30(1):163–171, 2004

**Affect perception**

The role of attention in affect perception: An examination of Mirsky's four factor model of attention in chronic schizophrenia, 30(4):727–738, 2004

**Affective disorders.** *See also* specific disorders

Age-at-first-registration for affective psychosis and schizophrenia, 30(4):849–853, 2004

Followup of psychotic outpatients: Dimensions of delusions and work functioning in schizophrenia, 30(1):147–161, 2004

Interpersonal trauma and posttraumatic stress disorder in patients with severe mental illness: Demographic, clinical, and health correlates, 30(1):45–57, 2004

Orbitofrontal cortical dysfunction in akinetic catatonia: A functional magnetic resonance imaging study during negative emotional stimulation, 30(2):405–427, 2004

Who are patients on conventional antipsychotics?, 29(2):195–199, 2003

**Age, Beginning, Course study**

Modeling the early course of schizophrenia, 29(2):325–340, 2003

**Age factors**

Age-at-first-registration for affective psychosis and schizophrenia, 30(4):849–853, 2004

Clinical and etiopathogenic specificities of the French concept of *psychose hallucinatoire chronique* compared to schizophrenia, 30(1):173–184, 2004

Developmental pathology, dopamine, and stress: A model for the age of onset of schizophrenia symptoms, 30(4):875–900, 2004

Earlier age of first diagnosis in schizophrenia is related to impaired motor control, 30(2):351–360, 2004

Global intellectual impairment does not accelerate with age in patients with schizophrenia: A cross-sectional analysis, 29(3):509–517, 2003

Poor antipsychotic adherence among patients with schizophrenia: Medication and patient factors, 30(2):255–264, 2004

Suicide in schizophrenia: The Wessex Recent Inpatient Suicide Study: A retrospective case-control study of 51 suicides, 30(4):803–811, 2004

**Agranulocytosis**

Differential effectiveness of clozapine for patients nonresponsive to or intolerant of first generation antipsychotic medications, 30(2):219–227, 2004

**AHs.** *See* Auditory hallucinations

**Akathisia**

The causes of underdiagnosing akathisia, 29(3):547–558, 2003

**Alcohol use and abuse**

Alcohol consumption and the CAGE test in outpatients with

- schizophrenia or schizoaffective disorder and in the general population, 30(4):947-956, 2004
- Caffeine intake in outpatients with schizophrenia, 30(4):935-945, 2004
- Alcoholism.** *See Alcohol use and abuse*
- Alzheimer's disease**
  - Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE): Alzheimer's disease trial, 29(1):57-72, 2003
  - Statistical approaches to effectiveness measurement and outcome-driven re-randomizations in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) studies, 29(1):73-80, 2003
- Amenorrhea**
  - Sexuality and schizophrenia: A review, 30(4):767-779, 2004
- Antidepressants.** *See also specific drugs*
  - The schizophrenia prodrome revisited: A neurodevelopmental perspective, 29(4):633-651, 2003
  - Trends in the rate and type of antipsychotic medications prescribed to persons with schizophrenia, 29(3):531-540, 2003
- Antioxidants**
  - Increased nitric oxide radicals in postmortem brain from patients with schizophrenia, 30(4):923-934, 2004
- Antipsychotics.** *See also specific drugs*
  - Adherence of schizophrenia pharmacotherapy to published treatment recommendations: Patient, facility, and provider predictors, 30(3):649-658, 2004
  - Atypical antipsychotics in first admission schizophrenia: Medication continuation and outcomes, 29(3):519-530, 2003
  - The causes of underdiagnosing akathisia, 29(3):547-558, 2003
  - Cerebrovascular response to cognitive tasks in patients with schizophrenia measured by near-infrared spectroscopy, 30(2):435-444, 2004
  - Changing environments and alternative perspectives in evaluating the cost-effectiveness of new antipsychotic drugs, 29(1):81-93, 2003
  - Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE): Alzheimer's disease trial, 29(1):57-72, 2003
  - Differential effectiveness of clozapine for patients nonresponsive to or intolerant of first generation antipsychotic medications, 30(2):219-227, 2004
  - The diffusion of new antipsychotic medications and formulary policy, 29(1):95-104, 2003
  - Duration of untreated psychosis and outcome of schizophrenia: Delay in intensive psychosocial treatment versus delay in treatment with antipsychotic medication, 29(2):341-348, 2003
  - Early treatment-induced improvement of negative symptoms predicts cognitive functioning in treatment-naïve first episode schizophrenia: A 2-year followup, 30(4):837-848, 2004
  - Effectiveness of atypical antipsychotic medications in reducing violent behavior among persons with schizophrenia in community-based treatment, 30(1):3-20, 2004
  - Generating evidence to inform policy and practice: The example of the second generation "atypical" antipsychotics, 29(1):105-114, 2003
  - The International Suicide Prevention Trial (InterSePT): Rationale and design of a trial comparing the relative ability of clozapine and olanzapine to reduce suicidal behavior in schizophrenia and schizoaffective patients, 30(3):577-586, 2004
  - The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effective-
  - ness (CATIE) project: Schizophrenia trial design and protocol development, 29(1):15-31, 2003
  - Neurocognitive assessment in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project schizophrenia trial: Development, methodology, and rationale, 29(1):45-55, 2003
  - Neurological soft signs and their relationship to cognitive and clinical efficacy of atypical antipsychotics in schizophrenia, 30(2):241-253, 2004
  - Poor antipsychotic adherence among patients with schizophrenia: Medication and patient factors, 30(2):255-264, 2004
  - PORT recommendations, 30(3):605-607, 2004
  - PORT treatment recommendations, 30(3):601-604, 2004
  - PORT updated treatment recommendations, 30(3):617-618, 2004
  - Racial disparity in the pharmacological management of schizophrenia, 29(2):183-193, 2003
  - Reduced red blood cell membrane essential polyunsaturated fatty acids in first episode schizophrenia at neuroleptic-naïve baseline, 30(4):901-911, 2004
  - Revised PORT recommendations, 30(3):609-611, 2004
  - The Schizophrenia Patient Outcomes Research Team (PORT): Updated treatment recommendations 2003, 30(2):193-217, 2004
  - The schizophrenia prodrome revisited: A neurodevelopmental perspective, 29(4):633-651, 2003
  - Science to services: Consumers need "real-world" science, 29(1):133-137, 2003
  - Sexuality and schizophrenia: A review, 30(4):767-779, 2004
  - Stages of change in smokers with schizophrenia or schizoaffective disorder and in the general population, 30(2):459-468, 2004

Statistical approaches to effectiveness measurement and outcome-driven re-randomizations in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) studies, 29(1):73–80, 2003

Trends in the rate and type of antipsychotic medications prescribed to persons with schizophrenia, 29(3):531–540, 2003

Validation of polypharmacy process measures in inpatient schizophrenia care, 30(4):1023–1033, 2004

Weight gain with clozapine compared to first generation antipsychotic medications, 30(2):229–240, 2004

Who are patients on conventional antipsychotics?, 29(2):195–199, 2003

#### **Antisocial personality disorder**

Comorbid personality disorders and substance use disorders of mentally ill homicide offenders: A structured clinical study on dual and triple diagnoses, 30(1):59–72, 2004

The correlates of comorbid antisocial personality disorder in schizophrenia, 30(4):791–802, 2004

#### **Anxiety disorders**

Offspring of parents with schizophrenia: Mental disorders during childhood and adolescence, 30(2):303–315, 2004

#### **APD. See Antisocial personality disorder**

#### **Aphasia**

Do people with schizophrenia comprehend what they read?, 29(3):499–507, 2003

#### **Assessment. See specific assessment instruments**

#### **Athens Study of Psychosis Prone-ness and Incidence of Schizophrenia**

Factorial composition of self-rated schizotypal traits among young males undergoing military training, 30(2):335–350, 2004

#### **Attention disorders**

Deficit versus negative syndrome in schizophrenia: Prediction of attentional impairment, 30(4):827–835, 2004

Latent inhibition and overswitching in schizophrenia, 30(4):713–726, 2004

#### **Atypical antipsychotics. See Antipsychotics; specific drugs**

#### **Auditory hallucinations**

Auditory hallucinations, source monitoring, and the belief that “voices” are real, 29(3):445–457, 2003

Correlates of the affective impact of auditory hallucinations in psychotic disorders, 30(1):163–171, 2004

#### **Auditory Verbal Learning Test**

Dynamic testing in schizophrenia: Does training change the construct validity of a test?, 30(4):703–711, 2004

#### **Avoidant personality disorder**

Offspring of parents with schizophrenia: Mental disorders during childhood and adolescence, 30(2):303–315, 2004

## **B**

#### **Bell-Lysaker Emotion Recognition Test**

The role of attention in affect perception: An examination of Mirsky's four factor model of attention in chronic schizophrenia, 30(4):727–738, 2004

#### **Bipolar disorder**

Commentary: Mental illness, society, stigma, and research, 30(3):573–575, 2004

At issue: Will the term brain disease reduce stigma and promote parity for mental illnesses?, 30(4):1043–1048, 2004

Overcoming barriers to research in early serious mental illness: Issues for future collaboration, 29(4):737–745, 2003

The Texas Medication Algorithm Project: Clinical results for schizophrenia, 30(3):627–647, 2004

#### **BMI. See Body mass index**

#### **Board-and-care homes**

Needs-based planning for persons with schizophrenia residing in board-and-care homes, 30(1):123–132, 2004

#### **Body mass index**

Weight gain with clozapine compared to first generation antipsychotic medications, 30(2):229–240, 2004

#### **Borderline personality disorder**

Overcoming barriers to research in early serious mental illness: Issues for future collaboration, 29(4):737–745, 2003

#### **Brain disease**

At issue: Stop the stigma: Call mental illness a brain disease, 30(3):477–479, 2004

At issue: Will the term brain disease reduce stigma and promote parity for mental illnesses?, 30(4):1043–1048, 2004

#### **Brain structure. See Neuroanatomy**

#### **Burden of illness. See also Cost-of-illness studies**

The disregarded caregivers: Subjective burden in spouses of schizophrenia patients, 30(3):665–675, 2004

The global costs of schizophrenia, 30(2):279–293, 2004

At issue: Siblings of patients with schizophrenia: Sibling bond, coping patterns, and fear of possible schizophrenia heredity, 30(2):445–458, 2004

## **C**

#### **Caffeine**

Caffeine intake in outpatients with schizophrenia, 30(4):935–945, 2004

#### **CAGE test**

Alcohol consumption and the CAGE test in outpatients with schizophrenia or schizoaffective disorder and in the general population, 30(4):947–956, 2004

# **Calgary Depression Scale**

The International Suicide Prevention Trial (InterSePT): Rationale and design of a trial comparing the relative ability of clozapine and olanzapine to reduce suicidal behavior in schizophrenia and schizoaffective patients, 30(3):577-586, 2004

# **Camberwell Assessment of Need**

Met and unmet needs of schizophrenia patients in a Spanish sample, 29(2):201-210, 2003

# **Caregiving**

The disregarded caregivers: Subjective burden in spouses of schizophrenia patients, 30(3):665-675, 2004

People with schizophrenia in five countries: Conceptual similarities and intercultural differences in family caregiving, 29(3):573-586, 2003

# **Case-control studies**

Suicide in schizophrenia: The Wessex Recent Inpatient Suicide Study: A retrospective case-control study of 51 suicides, 30(4):803-811, 2004

# **Catatonia**

Orbitofrontal cortical dysfunction in akinetic catatonia: A functional magnetic resonance imaging study during negative emotional stimulation, 30(2):405-427, 2004

# **CATIE. See Clinical Antipsychotic Trials of Intervention Effectiveness**

# **Cell membrane abnormalities**

Reduced red blood cell membrane essential polyunsaturated fatty acids in first episode schizophrenia at neuroleptic-naïve baseline, 30(4):901-911, 2004

# **Children. See also Adolescents**

Changing middle schoolers' attitudes about mental illness through education, 30(3):563-572, 2004

Creating school-age versions of semistructured interviews for the prodrome to schizophrenia:

Lessons from case reviews, 29(4):729-735, 2003

First person account: Schizophrenia and motherhood, 30(4):763-765, 2004

Offspring of parents with schizophrenia: Mental disorders during childhood and adolescence, 30(2):303-315, 2004

# **Clinical Antipsychotic Trials of Intervention Effectiveness**

Assessing clinical and functional outcomes in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial, 29(1):33-43, 2003

Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE): Alzheimer's disease trial, 29(1):57-72, 2003

Neurocognitive assessment in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project schizophrenia trial: Development, methodology, and rationale, 29(1):45-55, 2003

Science to services: Consumers need "real world" science, 29(1):133-137, 2003

Statistical approaches to effectiveness measurement and outcome-driven re-randomizations in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) studies, 29(1):73-80, 2003

# **Clinical Antipsychotic Trials of Intervention Effectiveness project**

The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: Schizophrenia trial design and protocol development, 29(1):15-31, 2003

# **Clinical trials. See also Clinical Antipsychotic Trials of Intervention Effectiveness**

Approaches to multisite clinical trials: The National Institute of

Mental Health perspective, 29(1):7-13, 2003

Changing environments and alternative perspectives in evaluating the cost-effectiveness of new antipsychotic drugs, 29(1):81-93, 2003

Estimating suicidality as outcome measure in clinical trials of suicide in schizophrenia, 30(3):587-598, 2004

Guest editors' introduction: What can large pragmatic clinical trials do for public mental health care?, 29(1):1-6, 2003

Overview of the First Annual Workshop on the Schizophrenia Prodrome, 29(4):625-631, 2003

What is ethically important in clinical research? A preliminary study of attitudes of 73 psychiatric faculty and residents, 29(3):607-613, 2003

# **Clozapine**

Changing environments and alternative perspectives in evaluating the cost-effectiveness of new antipsychotic drugs, 29(1):81-93, 2003

Differential effectiveness of clozapine for patients nonresponsive to or intolerant of first generation antipsychotic medications, 30(2):219-227, 2004

Estimating suicidality as outcome measure in clinical trials of suicide in schizophrenia, 30(3):587-598, 2004

Generating evidence to inform policy and practice: The example of the second generation "atypical" antipsychotics, 29(1):105-114, 2003

The International Suicide Prevention Trial (InterSePT): Rationale and design of a trial comparing the relative ability of clozapine and olanzapine to reduce suicidal behavior in schizophrenia and schizoaffective patients, 30(3):577-586, 2004

The National Institute of Mental Health Clinical Antipsychotic



Trials of Intervention Effectiveness (CATIE) project: Schizophrenia trial design and protocol development, 29(1):15-31, 2003  
 PORT updated treatment recommendations, 30(3):617-618, 2004

Trends in the rate and type of antipsychotic medications prescribed to persons with schizophrenia, 29(3):531-540, 2003

Weight gain with clozapine compared to first generation antipsychotic medications, 30(2):229-240, 2004

### Cognition

Cerebrovascular response to cognitive tasks in patients with schizophrenia measured by near-infrared spectroscopy, 30(2):435-444, 2004

The cognitive basis of disorganization symptomatology in schizophrenia and its clinical correlates: Toward a pathogenetic approach to disorganization, 29(3):459-471, 2003

Dynamic testing in schizophrenia: Does training change the construct validity of a test?, 30(4):703-711, 2004

Early treatment-induced improvement of negative symptoms predicts cognitive functioning in treatment-naïve first episode schizophrenia: A 2-year followup, 30(4):837-848, 2004

Investigating graphesthesia task performance in the biological relatives of schizophrenia patients, 30(2):327-334, 2004

Neurocognitive assessment in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project schizophrenia trial: Development, methodology, and rationale, 29(1):45-55, 2003

Neuromotor functioning in adolescents with schizotypal personality disorder: Associations with symptoms and neurocognition, 29(2):285-298, 2003

Overview of the First Annual Workshop on the Schizophrenia Prodrome, 29(4):625-631, 2003

Performance of schizophrenia patients on time-, event-, and activity-based prospective memory tasks, 30(4):693-701, 2004

The role of attention in affect perception: An examination of Mirsky's four factor model of attention in chronic schizophrenia, 30(4):727-738, 2004

A six-factor model of cognition in schizophrenia and related psychotic disorders: Relationships with clinical symptoms and functional capacity, 30(4):739-754, 2004

The Texas Medication Algorithm Project: Clinical results for schizophrenia, 30(3):627-647, 2004

### Cognitive behavioral therapy

Hallucination focused integrative treatment: A randomized controlled trial, 30(1):133-145, 2004

### Cognitive impairment

Absence of additional cognitive impairment in schizophrenia patients during maintenance electroconvulsive therapy, 30(1):185-189, 2004

Coping style in schizophrenia: Associations with neurocognitive deficits and personality, 30(1):113-121, 2004

Global intellectual impairment does not accelerate with age in patients with schizophrenia: A cross-sectional analysis, 29(3):509-517, 2003

The influence of a working memory load manipulation on language production in schizophrenia, 29(3):473-485, 2003

At issue: The future of cognitive rehabilitation of schizophrenia, 30(4):679-692, 2004

Neurocognitive assessment in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project schizophrenia

trial: Development, methodology, and rationale, 29(1):45-55, 2003

Neurological soft signs and their relationship to cognitive and clinical efficacy of atypical antipsychotics in schizophrenia, 30(2):241-253, 2004

A review and new report of medial temporal lobe dysfunction as a vulnerability indicator for schizophrenia: A magnetic resonance imaging morphometric family study of the parahippocampal gyrus, 29(4):803-830, 2003

The schizophrenia prodrome revisited: A neurodevelopmental perspective, 29(4):633-651, 2003

Which executive skills should we target to affect social functioning and symptom change? A study of a cognitive remediation therapy program, 30(1):87-100, 2004

### Cognitive remediation therapy

Which executive skills should we target to affect social functioning and symptom change? A study of a cognitive remediation therapy program, 30(1):87-100, 2004

### Cognitive training

A review of cognitive training in schizophrenia, 29(2):359-382, 2003

### Cohort studies

The correlates of comorbid antisocial personality disorder in schizophrenia, 30(4):791-802, 2004

Current and future forecasts of service use and expenditures of Medicaid-eligible schizophrenia patients in the state of Georgia, 30(4):983-995, 2004

Direct costs of schizophrenia and related disorders in Italian community mental health services: A multicenter, prospective 1-year followup study, 30(2):295-302, 2004

Factorial composition of self-rated schizotypal traits among young males undergoing military training, 30(2):335-350, 2004



- Multiple dimensions of schizotypy in first degree biological relatives of schizophrenia patients, 30(2):317–325, 2004
- Offspring of parents with schizophrenia: Mental disorders during childhood and adolescence, 30(2):303–315, 2004
- Psychotic symptoms among male adolescent detainees in The Netherlands, 30(1):73–86, 2004
- Satisfaction with mental health services among people with schizophrenia in five European sites: Results from the EPSILON study, 29(2):229–245, 2003
- Stages of change in smokers with schizophrenia or schizoaffective disorder and in the general population, 30(2):459–468, 2004
- Validation of polypharmacy process measures in inpatient schizophrenia care, 30(4):1023–1033, 2004
- Combination therapy**
- Add-on fluvoxamine improves primary negative symptoms: Evidence for specificity from response analysis of individual symptoms, 29(3):541–546, 2003
- Combined Attention Test**
- Latent inhibition and overswitching in schizophrenia, 30(4):713–726, 2004
- Communication disorders**
- The cognitive basis of disorganization symptomatology in schizophrenia and its clinical correlates: Toward a pathogenetic approach to disorganization, 29(3):459–471, 2003
- Community care**
- Current and future forecasts of service use and expenditures of Medicaid-eligible schizophrenia patients in the state of Georgia, 30(4):983–995, 2004
- Direct costs of schizophrenia and related disorders in Italian community mental health services: A multicenter, prospective 1-year followup study, 30(2):295–302, 2004
- Effectiveness of atypical antipsychotic medications in reducing violent behavior among persons with schizophrenia in community-based treatment, 30(1):3–20, 2004
- PORT updated treatments recommendations, 30(3):617–618, 2004
- Satisfaction with mental health services among people with schizophrenia in five European sites: Results from the EPSILON study, 29(2):229–245, 2003
- Community efforts**
- From stigma to discrimination: An analysis of community efforts to reduce the negative consequences of having a psychiatric disorder and label, 30(3):493–509, 2004
- Comorbidity**
- Comorbid personality disorders and substance use disorders of mentally ill homicide offenders: A structured clinical study on dual and triple diagnoses, 30(1):59–72, 2004
- The correlates of comorbid antisocial personality disorder in schizophrenia, 30(4):791–802, 2004
- Interpersonal trauma and posttraumatic stress disorder in patients with severe mental illness: Demographic, clinical, and health correlates, 30(1):45–57, 2004
- Compliance issues**
- Adherence of schizophrenia pharmacotherapy to published treatment recommendations: Patient, facility, and provider predictors, 30(3):649–658, 2004
- Effectiveness of atypical antipsychotic medications in reducing violent behavior among persons with schizophrenia in community-based treatment, 30(1):3–20, 2004
- Poor antipsychotic adherence among patients with schizophrenia: Medication and patient factors, 30(2):255–264, 2004
- Revised PORT recommendations, 30(3):609–611, 2004
- The schizophrenia prodrome revisited: A neurodevelopmental perspective, 29(4):633–651, 2003
- Sexuality and schizophrenia: A review, 30(4):767–779, 2004
- Who are patients on conventional antipsychotics?, 29(2):195–199, 2003
- Comprehensive Assessment of At Risk Mental States**
- Creating school-age versions of semistructured interviews for the prodrome to schizophrenia: Lessons from case reviews, 29(4):729–735, 2003
- Conduct disorder**
- The correlates of comorbid antisocial personality disorder in schizophrenia, 30(4):791–802, 2004
- Conflicts of interest**
- At issue: A model for academic/industry collaboration, 30(4):992–1004, 2004
- Consciousness**
- Schizophrenia, consciousness, and the self, 29(3):427–444, 2003
- Consumers**
- Science to services: Consumers need “real world” science, 29(1):133–137, 2003
- Coping strategies**
- Coping style in schizophrenia: Associations with neurocognitive deficits and personality, 30(1):113–121, 2004
- Hallucination focused integrative treatment: A randomized controlled trial, 30(1):133–145, 2004
- At issue: Siblings of patients with schizophrenia: Sibling bond, coping patterns, and fear of possible schizophrenia heredity, 30(2):445–458, 2004
- When does experience of psychosis result in a need for care? A prospective general population study, 29(2):349–358, 2003

## Cortisol

The stress cascade and schizophrenia: Etiology and onset, 29(4):671-692, 2003

## Cost analyses

Current and future forecasts of service use and expenditures of Medicaid-eligible schizophrenia patients in the state of Georgia, 30(4):983-995, 2004

The diffusion of new antipsychotic medications and formulary policy, 29(1):95-104, 2003

Generating evidence to inform policy and practice: The example of the second generation "atypical" antipsychotics, 29(1):105-114, 2003

Preference weights for cost-outcome analyses of schizophrenia treatments: Comparison of four stakeholder groups, 29(2):257-266, 2003

Science to services: Consumers need "real world" science, 29(1):133-137, 2003

## Cost-effectiveness studies

Changing environments and alternative perspectives in evaluating the cost-effectiveness of new antipsychotic drugs, 29(1):81-93, 2003

Hallucination focused integrative treatment: A randomized controlled trial, 30(1):133-145, 2004

## Cost-of-illness studies. *See also* Burden of illness

Direct costs of schizophrenia and related disorders in Italian community mental health services: A multicenter, prospective 1-year followup study, 30(2):295-302, 2004

The global costs of schizophrenia, 30(2):279-293, 2004

## Course and outcome. *See also* Schizophrenia Patient Outcomes Research Team

Adherence of schizophrenia pharmacotherapy to published treatment recommendations: Patient, facility, and provider predictors, 30(3):649-658, 2004

Assessing clinical and functional outcomes in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial, 29(1):33-43, 2003

Atypical antipsychotics in first admission schizophrenia: Medication continuation and outcomes, 29(3):519-530, 2003

Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE): Alzheimer's disease trial, 29(1):57-72, 2003

The correlates of comorbid antisocial personality disorder in schizophrenia, 30(4):791-802, 2004

Creating school-age versions of semistructured interviews for the prodrome to schizophrenia: Lessons from case reviews, 29(4):729-735, 2003

Duration of untreated psychosis and outcome of schizophrenia: Delay in intensive psychosocial treatment versus delay in treatment with antipsychotic medication, 29(2):341-348, 2003

Early treatment-induced improvement of negative symptoms predicts cognitive functioning in treatment-naïve first episode schizophrenia: A 2-year followup, 30(4):837-848, 2004

Estimating suicidality as outcome measure in clinical trials of suicide in schizophrenia, 30(3):587-598, 2004

Examining the factor structure of the Recovery Assessment Scale, 30(4):1035-1041, 2004

Half-full but nearly empty: Implications of the Schizophrenia PORT updated treatment recommendations, 30(3):619-621, 2004

Is emotion processing a predictor of functional outcome in schizophrenia?, 29(3):487-497, 2003

At issue: The future of cognitive rehabilitation of schizophrenia, 30(4):679-692, 2004

Modeling the early course of schizophrenia, 29(2):325-340, 2003

Neurocognitive assessment in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project schizophrenia trial: Development, methodology, and rationale, 29(1):45-55, 2003

People with schizophrenia in five countries: Conceptual similarities and intercultural differences in family caregiving, 29(3):573-586, 2003

Prolonged untreated illness duration from prodromal onset predicts outcome in first episode psychoses, 29(4):757-769, 2003

A randomized controlled trial of integrated versus parallel housing services for homeless adults with severe mental illness, 30(4):969-982, 2004

Satisfaction with mental health services among people with schizophrenia in five European sites: Results from the EPSILON study, 29(2):229-245, 2003

The Schizophrenia Care and Assessment Program Health Questionnaire (SCAP-HQ): An instrument to assess outcomes of schizophrenia care, 29(2):247-256, 2003

The Schizophrenia Patient Outcomes Research Team (PORT): Updated treatment recommendations 2003, 30(2):193-217, 2004

The schizophrenia prodrome revisited: A neurodevelopmental perspective, 29(4):633-651, 2003

Statistical approaches to effectiveness measurement and outcome-driven re-randomizations in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) studies, 29(1):73-80, 2003

Supportive therapy for schizophrenia: Possible mechanisms and implications for adjunctive psychosocial treatments, 30(1):101-112, 2004

The Texas Medication Algorithm Project: Clinical results for schizophrenia, 30(3):627-647, 2004

Transition to schizophrenia and related disorders: Toward a taxonomy of risk, 29(4):693-701, 2003

Treatment models and designs for intervention research during the psychotic prodrome, 29(4):747-756, 2003

Updated Schizophrenia PORT treatment recommendations, 30(3):623-625, 2004

Validation of polypharmacy process measures in inpatient schizophrenia care, 30(4):1023-1033, 2004

#### **Covi Anxiety Scale**

The International Suicide Prevention Trial (InterSePT): Rationale and design of a trial comparing the relative ability of clozapine and olanzapine to reduce suicidal behavior in schizophrenia and schizoaffective patients, 30(3):577-586, 2004

#### **Criminal behavior. See also Violence**

Comorbid personality disorders and substance use disorders of mentally ill homicide offenders: A structured clinical study on dual and triple diagnoses, 30(1):59-72, 2004

Psychotic symptoms among male adolescent detainees in The Netherlands, 30(1):73-86, 2004

#### **CRT. See Cognitive remediation therapy**

#### **CT. See Cognitive training**

#### **Cultural factors. See also Racial factors**

Disease management in Latinos with schizophrenia: A family-assisted, skills training approach, 29(2):211-227, 2003

People with schizophrenia in five countries: Conceptual similarities and intercultural differences in family caregiving, 29(3):573-586, 2003

#### **Curriculum**

Changing middle schoolers' attitudes about mental illness through education, 30(3):563-572, 2004

### **D**

#### **Dangerousness**

Images of mental illness in the media: Identifying gaps in the research, 30(3):543-561, 2004

At issue: Stop the stigma: Call mental illness a brain disease, 30(3):477-479, 2004

The stereotype of schizophrenia and its impact on discrimination against people with schizophrenia: Results from a representative survey in Germany, 30(4):1049-1061, 2004

#### **Decision making**

Assisted and surrogate decision making for pregnant patients who have schizophrenia, 30(3):659-664, 2004

#### **Deficit syndrome**

Deficit versus negative syndrome in schizophrenia: Prediction of attentional impairment, 30(4):827-835, 2004

#### **Delusions**

Auditory hallucinations, source monitoring, and the belief that "voices" are real, 29(3):445-457, 2003

Correlates of the affective impact of auditory hallucinations in psychotic disorders, 30(1):163-171, 2004

First person account: Living with the delusions and effects of schizophrenia, 29(4):877-879, 2003

Followup of psychotic outpatients: Dimensions of delusions and work functioning in schizophrenia, 30(1):147-161, 2004

Measuring delusional ideation: The 21-item Peters et al. Delusions Inventory (PDI), 30(4):1005-1022, 2004

Schizophrenia, delusional symptoms, and violence: The

threat/control-override concept reexamined, 30(1):31-44, 2004

#### **Dementia. See Alzheimer's disease**

#### **Demographics**

Interpersonal trauma and posttraumatic stress disorder in patients with severe mental illness: Demographic, clinical, and health correlates, 30(1):45-57, 2004

#### **Department of Veterans Affairs**

Adherence of schizophrenia pharmacotherapy to published treatment recommendations: Patient, facility, and provider predictors, 30(3):649-658, 2004

Changing environments and alternative perspectives in evaluating the cost-effectiveness of new antipsychotic drugs, 29(1):81-93, 2003

Poor antipsychotic adherence among patients with schizophrenia: Medication and patient factors, 30(2):255-264, 2004

#### **Dermatoglyphics**

Neurodevelopmental interactions conferring risk for schizophrenia: A study of dermatoglyphic markers in patients and relatives, 29(3):595-605, 2003

#### **Design Fluency Test**

Performance of schizophrenia patients on time-, event-, and activity-based prospective memory tasks, 30(4):693-701, 2004

#### **DFT. See Design Fluency Test**

#### **Diabetes**

Revised PORT recommendations, 30(3):609-611, 2004

#### **Diagnostic Interview Schedule for Children**

Psychotic symptoms among male adolescent detainees in The Netherlands, 30(1):73-86, 2004

#### **Diet. See Nutrition**

#### **DISC-2.3. See Diagnostic Interview Schedule for Children**

#### **Discriminant function analyses**

Multiple structural brain measures obtained by three-dimensional magnetic resonance imaging to distinguish between schizophre-

nia patients and normal subjects, 30(2):393-404, 2004

#### **Discrimination**

Changing middle schoolers' attitudes about mental illness through education, 30(3):563-572, 2004

Editors' introduction: Building mental illness stigma research, 30(3):473-475, 2004

Images of mental illness in the media: Identifying gaps in the research, 30(3):543-561, 2004

Measuring mental illness stigma, 30(3):511-541, 2004

The stereotype of schizophrenia and its impact on discrimination against people with schizophrenia: Results from a representative survey in Germany, 30(4):1049-1061, 2004

From stigma to discrimination: An analysis of community efforts to reduce the negative consequences of having a psychiatric disorder and label, 30(3):493-509, 2004

Structural levels of mental illness stigma and discrimination, 30(3):481-491, 2004

#### **Disease management**

Disease management in Latinos with schizophrenia: A family-assisted, skills training approach, 29(2):211-227, 2003

#### **Disorganization. See Dissociation**

#### **Dissociation**

The assessment of "prodromal schizophrenia": Unresolved issues and future directions, 29(4):717-728, 2003

The cognitive basis of disorganization symptomatology in schizophrenia and its clinical correlates: Toward a pathogenetic approach to disorganization, 29(3):459-471, 2003

#### **Documentary films**

The effects of a documentary film about schizophrenia on psychiatric stigma, 29(2):383-391, 2003

#### **Dopamine system**

Developmental pathology, dopamine, and stress: A model for the age of onset of schizophrenia symptoms, 30(4):875-900, 2004

#### **DUI. See Duration of untreated illness**

#### **Duration of untreated illness**

Duration of untreated psychosis and outcome of schizophrenia: Delay in intensive psychosocial treatment versus delay in treatment with antipsychotic medication, 29(2):341-348, 2003

Prolonged untreated illness duration from prodromal onset predicts outcome in first episode psychoses, 29(4):757-769, 2003

#### **Dynamic testing**

Dynamic testing in schizophrenia: Does training change the construct validity of a test?, 30(4):703-711, 2004

#### **Dyskinesia**

Earlier age of first diagnosis in schizophrenia is related to impaired motor control, 30(2):351-360, 2004

#### **Dyslipidemias**

Revised PORT recommendations, 30(3):609-611, 2004

## **E**

#### **Early intervention**

The "close-in" or ultra high-risk model: A safe and effective strategy for research and clinical intervention in prepsychotic mental disorder, 29(4):771-790, 2003

Commentary: Progress, issues, and implications of prodromal research: An inside view, 29(4):851-858, 2003

Commentary: Service system perspectives on early intervention research, 29(4):867-875, 2003

Creating school-age versions of semistructured interviews for the prodrome to schizophrenia: Lessons from case reviews, 29(4):729-735, 2003

Overcoming barriers to research in early serious mental illness: Issues for future collaboration, 29(4):737-745, 2003

Overview of the First Annual Workshop on the Schizophrenia Prodrome, 29(4):625-631, 2003

Prodromal assessment with the Structured Interview for Prodromal Syndromes and the Scale of Prodromal Symptoms: Predictive validity, interrater reliability, and training to reliability, 29(4):703-715, 2003

Prolonged untreated illness duration from prodromal onset predicts outcome in first episode psychoses, 29(4):757-769, 2003

Transition to schizophrenia and related disorders: Toward a taxonomy of risk, 29(4):693-701, 2003

Treatment models and designs for intervention research during the psychotic prodrome, 29(4):747-756, 2003

#### **ECAS. See Epidemiological Catchment Area Study**

#### **Emotion processing**

Is emotion processing a predictor of functional outcome in schizophrenia?, 29(3):487-497, 2003

Orbitofrontal cortical dysfunction in akinetic catatonia: A functional magnetic resonance imaging study during negative emotional stimulation, 30(2):405-427, 2004

#### **Employment**

Followup of psychotic outpatients: Dimensions of delusions and work functioning in schizophrenia, 30(1):147-161, 2004

#### **Environmental factors**

Early and late neurodevelopmental influences in the prodrome to schizophrenia: Contributions of genes, environment, and their interactions, 29(4):653-669, 2003

#### **Epidemiologic studies**

Alcohol consumption and the CAGE test in outpatients with



schizophrenia or schizoaffective disorder and in the general population, 30(4):947-956, 2004

The concept of population prevention: Application to schizophrenia, 29(4):791-801, 2003

Stages of change in smokers with schizophrenia or schizoaffective disorder and in the general population, 30(2):459-468, 2004

The stereotype of schizophrenia and its impact on discrimination against people with schizophrenia: Results from a representative survey in Germany, 30(4):1049-1061, 2004

A systematic review and meta-analysis of Northern Hemisphere season of birth studies in schizophrenia, 29(3):587-593, 2003

When does experience of psychosis result in a need for care? A prospective general population study, 29(2):349-358, 2003

#### **Epidemiological Catchment Area Study**

The correlates of comorbid antisocial personality disorder in schizophrenia, 30(4):791-802, 2004

#### **Epigenetic studies**

Monozygotic twins exhibit numerous epigenetic differences: Clues to twin discordance?, 29(1):169-178, 2003

#### **EPSILON study group. See European Psychiatric Services: Inputs Linked to Outcomes and Needs**

#### **Ethical considerations**

Assisted and surrogate decision making for pregnant patients who have schizophrenia, 30(3):659-664, 2004

The "close-in" or ultra high-risk model: A safe and effective strategy for research and clinical intervention in prepsychotic mental disorder, 29(4):771-790, 2003

The International Suicide Prevention Trial (InterSePT): Rationale and design of a trial comparing

the relative ability of clozapine and olanzapine to reduce suicidal behavior in schizophrenia and schizoaffective patients, 30(3):577-586, 2004

What is ethically important in clinical research? A preliminary study of attitudes of 73 psychiatric faculty and residents, 29(3):607-613, 2003

#### **Ethnic factors. See Cultural factors; Racial factors**

#### **Etiology**

The correlates of comorbid antisocial personality disorder in schizophrenia, 30(4):791-802, 2004

Early and late neurodevelopmental influences in the prodrome to schizophrenia: Contributions of genes, environment, and their interactions, 29(4):653-669, 2003

At issue: Assessment of schizophrenia: Getting closer to the cause, 29(3):405-411, 2003

The nosology of psychotic disorders: A comparison among competing classification systems, 29(3):413-425, 2003

The stress cascade and schizophrenia: Etiology and onset, 29(4):671-692, 2003

#### **European Psychiatric Services: Inputs Linked to Outcomes and Needs**

People with schizophrenia in five countries: Conceptual similarities and intercultural differences in family caregiving, 29(3):573-586, 2003

Satisfaction with mental health services among people with schizophrenia in five European sites: Results from the EPSILON study, 29(2):229-245, 2003

#### **Evidence-based practices**

Disease management in Latinos with schizophrenia: A family-assisted, skills training approach, 29(2):211-227, 2003

Half-full but nearly empty: Implications of the Schizophrenia PORT

updated treatment recommendations, 30(3):619-621, 2004

Implementation of evidence-based practices in state mental health systems: Implications for research and effectiveness studies, 29(1):125-131, 2003

Inside the black box: The importance of monitoring treatment implementation, 30(3):613-615, 2004

Randomized controlled trials in evidence-based mental health care: Getting the right answer to the right question, 29(1):115-123, 2003

#### **Executive functioning**

Dynamic testing in schizophrenia: Does training change the construct validity of a test?, 30(4):703-711, 2004

Neurological soft signs and their relationship to cognitive and clinical efficacy of atypical antipsychotics in schizophrenia, 30(2):241-253, 2004

Which executive skills should we target to affect social functioning and symptom change? A study of a cognitive remediation therapy program, 30(1):87-100, 2004

#### **Extrapyramidal side effects. See also Adverse effects; Side effects**

Adherence of schizophrenia pharmacotherapy to published treatment recommendations: Patient, facility, and provider predictors, 30(3):649-658, 2004

Earlier age of first diagnosis in schizophrenia is related to impaired motor control, 30(2):351-360, 2004

Revised PORT recommendations, 30(3):609-611, 2004

## **F**

#### **Facial Emotion Identification Test**

The role of attention in affect perception: An examination of Mirsky's four factor model of attention in chronic schizophrenia, 30(4):727-738, 2004



## Factor analyses

Examining the factor structure of the Recovery Assessment Scale, 30(4):1035–1041, 2004

Factorial composition of self-rated schizotypal traits among young males undergoing military training, 30(2):335–350, 2004

Five latent factors underlying schizophrenia: Analysis and relationship to illnesses in relatives, 30(4):855–873, 2004

A six-factor model of cognition in schizophrenia and related psychotic disorders: Relationships with clinical symptoms and functional capacity, 30(4):739–754, 2004

## Family studies. *See also* Sibling studies; Spouses of patients; Twin studies

Early and late neurodevelopmental influences in the prodrome to schizophrenia: Contributions of genes, environment, and their interactions, 29(4):653–669, 2003

Elevated levels of schizotypal features in parents of patients with a family history of schizophrenia spectrum disorders, 30(4):781–790, 2004

Five latent factors underlying schizophrenia: Analysis and relationship to illnesses in relatives, 30(4):855–873, 2004

Investigating graphesthesia task performance in the biological relatives of schizophrenia patients, 30(2):327–334, 2004

Multiple dimensions of schizotypy in first degree biological relatives of schizophrenia patients, 30(2):317–325, 2004

Neurodevelopmental interactions conferring risk for schizophrenia: A study of dermatoglyphic markers in patients and relatives, 29(3):595–605, 2003

Offspring of parents with schizophrenia: Mental disorders during childhood and adolescence, 30(2):303–315, 2004

A review and new report of medial temporal lobe dysfunction as a vulnerability indicator for schizophrenia: A magnetic resonance imaging morphometric family study of the parahippocampal gyrus, 29(4):803–830, 2003

Schizotypal personality traits in nonpsychotic relatives are associated with positive symptoms in psychotic probands, 29(2):273–283, 2003

## FCBT. *See* Functional cognitive behavioral therapy

## First Annual Workshop of the Schizophrenia Prodrome

Overview of the First Annual Workshop on the Schizophrenia Prodrome, 29(4):625–631, 2003

## First-episode psychosis

The assessment of “prodromal schizophrenia”: Unresolved issues and future directions, 29(4):717–728, 2003

Atypical antipsychotics in first admission schizophrenia: Medication continuation and outcomes, 29(3):519–530, 2003

The “close-in” or ultra high-risk model: A safe and effective strategy for research and clinical intervention in prepsychotic mental disorder, 29(4):771–790, 2003

Commentary: Chickens and eggs; carts and horses: An outsider’s perspective on the study of the early stages and potential prevention of psychosis and schizophrenia, 29(4):845–849, 2003

Commentary: Progress, issues, and implications of prodromal research: An inside view, 29(4):851–858, 2003

Commentary: The schizophrenia prodrome: A high-risk concept, 29(4):859–865, 2003

Developmental pathology, dopamine, and stress: A model for the age of onset of schizophrenia symptoms, 30(4):875–900, 2004

Earlier age of first diagnosis in schizophrenia is related to impaired motor control, 30(2):351–360, 2004

Early and late neurodevelopmental influences in the prodrome to schizophrenia: Contributions of genes, environment, and their interactions, 29(4):653–669, 2003

Early treatment-induced improvement of negative symptoms predicts cognitive functioning in treatment-naïve first episode schizophrenia: A 2-year followup, 30(4):837–848, 2004

Editors’ introduction: New frontiers in prodromal research, 29(4):621–623, 2003

At issue: Sex and gender in schizophrenia, 30(4):755–762, 2004

Modeling the early course of schizophrenia, 29(2):325–340, 2003

Overcoming barriers to research in early serious mental illness: Issues for future collaboration, 29(4):737–745, 2003

Overview of the First Annual Workshop on the Schizophrenia Prodrome, 29(4):625–631, 2003

PORT treatment recommendations, 30(3):601–604, 2004

Premorbid functioning in schizophrenia: Relation to baseline symptoms, treatment response, and medication side effects, 30(2):265–278, 2004

Prodromal assessment with the Structured Interview for Prodromal Syndromes and the Scale of Prodromal Symptoms: Predictive validity, interrater reliability, and training to reliability, 29(4):703–715, 2003

Prolonged untreated illness duration from prodromal onset predicts outcome in first episode psychoses, 29(4):757–769, 2003

Proton magnetic resonance spectroscopy in first episode psychosis and ultra high-risk individuals, 29(4):831–843, 2003

Reduced red blood cell membrane essential polyunsaturated fatty

acids in first episode schizophrenia at neuroleptic-naïve baseline, 30(4):901-911, 2004

A review and new report of medial temporal lobe dysfunction as a vulnerability indicator for schizophrenia: A magnetic resonance imaging morphometric family study of the parahippocampal gyrus, 29(4):803-830, 2003

The schizophrenia prodrome revisited: A neurodevelopmental perspective, 29(4):633-651, 2003

The stress cascade and schizophrenia: Etiology and onset, 29(4):671-692, 2003

Transition to schizophrenia and related disorders: Toward a taxonomy of risk, 29(4):693-701, 2003

Treatment models and designs for intervention research during the psychotic prodrome, 29(4):747-756, 2003

**First person accounts.** *See Subjective experiences*

#### Fluvoxamine

Add-on fluvoxamine improves primary negative symptoms: Evidence for specificity from response analysis of individual symptoms, 29(3):541-546, 2003

**fMRI.** *See Functional magnetic resonance imaging*

**Followup studies.** *See also Longitudinal studies*

Are negative symptoms associated with functioning deficits in both schizophrenia and nonschizophrenia patients? A 10-year longitudinal analysis, 30(4):813-825, 2004

The assessment of "prodromal schizophrenia": Unresolved issues and future directions, 29(4):717-728, 2003

Atypical antipsychotics in first admission schizophrenia: Medication continuation and outcomes, 29(3):519-530, 2003

Direct costs of schizophrenia and related disorders in Italian community mental health services: A

multicenter, prospective 1-year followup study, 30(2):295-302, 2004

Early treatment-induced improvement of negative symptoms predicts cognitive functioning in treatment-naïve first episode schizophrenia: A 2-year followup, 30(4):837-848, 2004

Effectiveness of atypical antipsychotic medications in reducing violent behavior among persons with schizophrenia in community-based treatment, 30(1):3-20, 2004

Followup of psychotic outpatients: Dimensions of delusions and work functioning in schizophrenia, 30(1):147-161, 2004

Hallucination focused integrative treatment: A randomized controlled trial, 30(1):133-145, 2004

Prolonged untreated illness duration from prodromal onset predicts outcome in first episode psychoses, 29(4):757-769, 2003

The Texas Medication Algorithm Project: Clinical results for schizophrenia, 30(3):627-647, 2004

What is schizophrenic in acute and transient psychotic disorder?, 29(2):311-323, 2003

#### Formulary policies

The diffusion of new antipsychotic medications and formulary policy, 29(1):95-104, 2003

Science to services: Consumers need "real world" science, 29(1):133-137, 2003

#### Free radicals

Increased nitric oxide radicals in postmortem brain from patients with schizophrenia, 30(4):923-934, 2004

#### Functional cognitive behavioral therapy

Supportive therapy for schizophrenia: Possible mechanisms and implications for adjunctive psychosocial treatments, 30(1):101-112, 2004

#### Functional impairment. *See also Social functioning*

Are negative symptoms associated with functioning deficits in both schizophrenia and nonschizophrenia patients? A 10-year longitudinal analysis, 30(4):813-825, 2004

Assessing clinical and functional outcomes in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial, 29(1):33-43, 2003

The Multidimensional Scale of Independent Functioning: A new instrument for measuring functional disability in psychiatric populations, 29(1):153-167, 2003

Premorbid functioning in schizophrenia: Relation to baseline symptoms, treatment response, and medication side effects, 30(2):265-278, 2004

Prolonged untreated illness duration from prodromal onset predicts outcome in first episode psychoses, 29(4):757-769, 2003

Treatment models and designs for intervention research during the psychotic prodrome, 29(4):747-756, 2003

#### Functional magnetic resonance imaging

Orbitofrontal cortical dysfunction in akinetic catatonia: A functional magnetic resonance imaging study during negative emotional stimulation, 30(2):405-427, 2004

## G

#### GAF. *See Global Assessment of Functioning Scale*

#### Gender factors. *See also Sex factors*

Age-at-first-registration for affective psychosis and schizophrenia, 30(4):849-853, 2004

Caffeine intake in outpatients with schizophrenia, 30(4):935-945, 2004

- Clinical and etiopathogenic specificities of the French concept of psychoses hallucinatoires chroniques compared to schizophrenia, 30(1):173–184, 2004
- The correlates of comorbid antisocial personality disorder in schizophrenia, 30(4):791–802, 2004
- Factorial composition of self-rated schizotypal traits among young males undergoing military training, 30(2):335–350, 2004
- At issue: Sex and gender in schizophrenia, 30(4):755–762, 2004
- Multiple structural brain measures obtained by three-dimensional magnetic resonance imaging to distinguish between schizophrenia patients and normal subjects, 30(2):393–404, 2004
- Offspring of parents with schizophrenia: Mental disorders during childhood and adolescence, 30(2):303–315, 2004
- Premorbid functioning in schizophrenia: Relation to baseline symptoms, treatment response, and medication side effects, 30(2):265–278, 2004
- Psychotic symptoms among male adolescent detainees in The Netherlands, 30(1):73–86, 2004
- Study of sexuality-related characteristics in young adults with schizophrenia treated with novel neuroleptics and in a comparison group of young adults, 29(3):559–572, 2003
- Suicide in schizophrenia: The Wessex Recent Inpatient Suicide Study: A retrospective case-control study of 51 suicides, 30(4):803–811, 2004
- Trends in the rate and type of antipsychotic medications prescribed to persons with schizophrenia, 29(3):531–540, 2003
- Weight gain with clozapine compared to first generation antipsychotic medications, 30(2):229–240, 2004
- What is schizophrenic in acute and transient psychotic disorder?, 29(2):311–323, 2003
- Genetic factors**
- Aggregability of red blood cells of schizophrenia patients with negative syndrome is selectively enhanced, 30(4):913–922, 2004
- Clinical and etiopathogenic specificities of the French concept of psychoses hallucinatoires chroniques compared to schizophrenia, 30(1):173–184, 2004
- The cognitive basis of disorganization symptomatology in schizophrenia and its clinical correlates: Toward a pathogenetic approach to disorganization, 29(3):459–471, 2003
- Early and late neurodevelopmental influences in the prodrome to schizophrenia: Contributions of genes, environment, and their interactions, 29(4):653–669, 2003
- Elevated levels of schizotypal features in parents of patients with a family history of schizophrenia spectrum disorders, 30(4):781–790, 2004
- Five latent factors underlying schizophrenia: Analysis and relationship to illnesses in relatives, 30(4):855–873, 2004
- Investigating graphesthesia task performance in the biological relatives of schizophrenia patients, 30(2):327–334, 2004
- At issue: Assessment of schizophrenia: Getting closer to the cause, 29(3):405–411, 2003
- At issue: Siblings of patients with schizophrenia: Sibling bond, coping patterns, and fear of possible schizophrenia heredity, 30(2):445–458, 2004
- Multiple dimensions of schizotypy in first degree biological relatives of schizophrenia patients, 30(2):317–325, 2004
- Neurodevelopmental interactions conferring risk for schizophrenia: A study of dermatoglyphic markers in patients and relatives, 29(3):595–605, 2003
- Offspring of parents with schizophrenia: Mental disorders during childhood and adolescence, 30(2):303–315, 2004
- A review and new report of medial temporal lobe dysfunction as a vulnerability indicator for schizophrenia: A magnetic resonance imaging morphometric family study of the parahippocampal gyrus, 29(4):803–830, 2003
- Schizotypal personality traits in nonpsychotic relatives are associated with positive symptoms in psychotic probands, 29(2):273–283, 2003
- Using neurophysiological markers of genetic risk to define the boundaries of the schizophrenia spectrum phenotype, 29(2):299–309, 2003
- What is schizophrenic in acute and transient psychotic disorder?, 29(2):311–323, 2003
- Geographic factors.** *See also specific geographical areas, e.g., Germany*
- A systematic review and meta-analysis of Northern Hemisphere season of birth studies in schizophrenia, 29(3):587–593, 2003
- Georgia**
- Current and future forecasts of service use and expenditures of Medicaid-eligible schizophrenia patients in the state of Georgia, 30(4):983–995, 2004
- Germany**
- The stereotype of schizophrenia and its impact on discrimination against people with schizophrenia: Results from a representative survey in Germany, 30(4):1049–1061, 2004
- Global Assessment of Functioning Scale**
- Prolonged untreated illness duration from prodromal onset predicts outcome in first episode psychoses, 29(4):757–769, 2003

## Glutamate system

Developmental pathology, dopamine, and stress: A model for the age of onset of schizophrenia symptoms, 30(4):875-900, 2004

## Graphesthesia

Investigating graphesthesia task performance in the biological relatives of schizophrenia patients, 30(2):327-334, 2004

## Greece

Factorial composition of self-rated schizotypal traits among young males undergoing military training, 30(2):335-350, 2004

# H

## Hallucination focused integrative treatment

Hallucination focused integrative treatment: A randomized controlled trial, 30(1):133-145, 2004

## Hallucinations

Clinical and etiopathogenic specificities of the French concept of *psychose hallucinatoire chronique* compared to schizophrenia, 30(1):173-184, 2004

First person account: The clogs, 30(1):191-192

## Haloperidol

Changing environments and alternative perspectives in evaluating the cost-effectiveness of new antipsychotic drugs, 29(1):81-93, 2003

## Health problems

Interpersonal trauma and posttraumatic stress disorder in patients with severe mental illness: Demographic, clinical, and health correlates, 30(1):45-57, 2004

## HIT. See Hallucination focused integrative treatment

## Homelessness

A randomized controlled trial of integrated versus parallel housing services for homeless adults with severe mental illness, 30(4):969-982, 2004

## Homicide

Comorbid personality disorders and substance use disorders of mentally ill homicide offenders: A structured clinical study on dual and triple diagnoses, 30(1):59-72, 2004

## Housing services

Needs-based planning for persons with schizophrenia residing in board-and-care homes, 30(1):123-132, 2004

A randomized controlled trial of integrated versus parallel housing services for homeless adults with severe mental illness, 30(4):969-982, 2004

## Hyperreflexivity

Schizophrenia, consciousness, and the self, 29(3):427-444, 2003

## Hypothalamic-pituitary-adrenal system

Developmental pathology, dopamine, and stress: A model for the age of onset of schizophrenia symptoms, 30(4):875-900, 2004

# I

## IEQ. See Involvement Evaluation Questionnaire

## In Our Own Voice: Living With Mental Illness

Commentary: Mental illness, society, stigma, and research, 30(3):573-575, 2004

## Insight

First person account: How insight poetry helped me to overcome my illness, 30(2):469-472, 2004

## Intelligence quotient

Dynamic testing in schizophrenia: Does training change the construct validity of a test?, 30(4):703-711, 2004

Global intellectual impairment does not accelerate with age in patients with schizophrenia: A cross-sectional analysis, 29(3):509-517, 2003

## International Affective Picture System

Orbitofrontal cortical dysfunction in akinetic catatonia: A functional magnetic resonance imaging study during negative emotional stimulation, 30(2):405-427, 2004

## International Prodromal Research Network

Editors' introduction: New frontiers in prodromal research, 29(4):621-623, 2003

Overview of the First Annual Workshop on the Schizophrenia Prodrome, 29(4):625-631, 2003

## International Suicide Prevention Trial

Estimating suicidality as outcome measure in clinical trials of suicide in schizophrenia, 30(3):587-598, 2004

The International Suicide Prevention Trial (InterSePT): Rationale and design of a trial comparing the relative ability of clozapine and olanzapine to reduce suicidal behavior in schizophrenia and schizoaffective patients, 30(3):577-586, 2004

## InterSePT. See International Suicide Prevention Trial

## Interview for the Retrospective Assessment of the Onset of Schizophrenia

Modeling the early course of schizophrenia, 29(2):325-340, 2003

## Involvement Evaluation Questionnaire

People with schizophrenia in five countries: Conceptual similarities and intercultural differences in family caregiving, 29(3):573-586, 2003

## IPRN. See International Prodromal Research Network

## IRAOS. See Interview for the Retrospective Assessment of the Onset of Schizophrenia

## Italy

Direct costs of schizophrenia and related disorders in Italian community mental health services: A multicenter, prospective 1-year



followup study, 30(2):295-302, 2004

## J

**Juvenile delinquency.** *See* Criminal behavior; Violence

## L

**Labeling.** *See* Stigma  
**Language**

The influence of a working memory load manipulation on language production in schizophrenia, 29(3):473-485, 2003

**Latent class analyses**

The nosology of psychotic disorders: A comparison among competing classification systems, 29(3):413-425, 2003

**Latent inhibition**

Latent inhibition and overswitching in schizophrenia, 30(4):713-726, 2004

**LCA.** *See* Latent class analyses

**Letter number span test**

Cerebrovascular response to cognitive tasks in patients with schizophrenia measured by near-infrared spectroscopy, 30(2):435-444, 2004

**Leukopenia**

Differential effectiveness of clozapine for patients nonresponsive to or intolerant of first generation antipsychotic medications, 30(2):219-227, 2004

**LI.** *See* Latent inhibition

**Literature reviews**

Developmental pathology, dopamine, and stress: A model for the age of onset of schizophrenia symptoms, 30(4):875-900, 2004

The global costs of schizophrenia, 30(2):279-293, 2004

Images of mental illness in the media: Identifying gaps in the research, 30(3):543-561, 2004

Measuring mental illness stigma, 30(3):511-541, 2004

PORT recommendations, 30(3):605-607, 2004

PORT treatment recommendations, 30(3):601-604, 2004

A review and new report of medial temporal lobe dysfunction as a vulnerability indicator for schizophrenia: A magnetic resonance imaging morphometric family study of the parahippocampal gyrus, 29(4):803-830, 2003

Sexuality and schizophrenia: A review, 30(4):767-779, 2004

**LN.** *See* Letter number span test

**Longitudinal studies.** *See also* Followup studies

Are negative symptoms associated with functioning deficits in both schizophrenia and nonschizophrenia patients? A 10-year longitudinal analysis, 30(4):813-825, 2004

Effectiveness of atypical antipsychotic medications in reducing violent behavior among persons with schizophrenia in community-based treatment, 30(1):3-20, 2004

Followup of psychotic outpatients: Dimensions of delusions and work functioning in schizophrenia, 30(1):147-161, 2004

A review and new report of medial temporal lobe dysfunction as a vulnerability indicator for schizophrenia: A magnetic resonance imaging morphometric family study of the parahippocampal gyrus, 29(4):803-830, 2003

## M

**M-ECT.** *See* Maintenance electroconvulsive therapy

**Magnetic resonance imaging**

Early and late neurodevelopmental influences in the prodrome to schizophrenia: Contributions of genes, environment, and their interactions, 29(4):653-669, 2003

Multiple structural brain measures obtained by three-dimensional

magnetic resonance imaging to distinguish between schizophrenia patients and normal subjects, 30(2):393-404, 2004

A review and new report of medial temporal lobe dysfunction as a vulnerability indicator for schizophrenia: A magnetic resonance imaging morphometric family study of the parahippocampal gyrus, 29(4):803-830, 2003

**Magnetic resonance spectroscopy**

Proton magnetic resonance spectroscopy in first episode psychosis and ultra high-risk individuals, 29(4):831-843, 2003

**Mail surveys**

Alcohol consumption and the CAGE test in outpatients with schizophrenia or schizoaffective disorder and in the general population, 30(4):947-956, 2004

Stages of change in smokers with schizophrenia or schizoaffective disorder and in the general population, 30(2):459-468, 2004

Maintenance electroconvulsive therapy

Absence of additional cognitive impairment in schizophrenia patients during maintenance electroconvulsive therapy, 30(1):185-189, 2004

**Major depressive disorder**

At issue: Will the term brain disease reduce stigma and promote parity for mental illnesses?, 30(4):1043-1048, 2004

The Texas Medication Algorithm Project: Clinical results for schizophrenia, 30(3):627-647, 2004

**Media**

Commentary: Mental illness, society, stigma, and research, 30(3):573-575, 2004

Images of mental illness in the media: Identifying gaps in the research, 30(3):543-561, 2004

**Medicaid**

Current and future forecasts of service use and expenditures of Medicaid-eligible schizophrenia

patients in the state of Georgia, 30(4):983-995, 2004

Science to services: Consumers need "real world" science, 29(1):133-137, 2003

#### Medicare

Current and future forecasts of service use and expenditures of Medicaid-eligible schizophrenia patients in the state of Georgia, 30(4):983-995, 2004

**Medications.** *See Antipsychotics; Prescribing practices; specific drugs and classes of drugs*

**Memory.** *See Cognition; Cognitive impairment*

**Mental illness.** *See also Psychoses; specific disorders*

Changing middle schoolers' attitudes about mental illness through education, 30(3):563-572, 2004

Commentary: Mental illness, society, stigma, and research, 30(3):573-575, 2004

Examining the factor structure of the Recovery Assessment Scale, 30(4):1035-1041, 2004

Images of mental illness in the media: Identifying gaps in the research, 30(3):543-561, 2004

At Issue: Stop the stigma: Call mental illness a brain disease, 30(3):477-479, 2004

At issue: Will the term brain disease reduce stigma and promote parity for mental illnesses?, 30(4):1043-1048, 2004

A randomized controlled trial of integrated versus parallel housing services for homeless adults with severe mental illness, 30(4):969-982, 2004

From stigma to discrimination: An analysis of community efforts to reduce the negative consequences of having a psychiatric disorder and label, 30(3):493-509, 2004

Structural levels of mental illness stigma and discrimination, 30(3):481-491, 2004

#### Meta-analyses

Sleep in untreated patients with schizophrenia: A meta-analysis, 30(4):957-967, 2004

A systematic review and meta-analysis of Northern Hemisphere season of birth studies in schizophrenia, 29(3):587-593, 2003

#### Minor physical anomalies

Discriminating value of total minor physical anomaly score on the Waldrop Physical Anomaly Scale between schizophrenia patients and normal control subjects, 30(2):361-366, 2004

#### Mirsky's four factor model of attention

The role of attention in affect perception: An examination of Mirsky's four factor model of attention in chronic schizophrenia, 30(4):727-738, 2004

#### Motivation

Psychotic motivation and the paradox of current research on serious mental illness and rates of violence, 30(1):21-30, 2004

#### Motor control impairment

Earlier age of first diagnosis in schizophrenia is related to impaired motor control, 30(2):351-360, 2004

Orbitofrontal cortical dysfunction in akinetic catatonia: A functional magnetic resonance imaging study during negative emotional stimulation, 30(2):405-427, 2004

**MPAs.** *See Minor physical anomalies*

**MRI.** *See Magnetic resonance imaging*

**MRS.** *See Magnetic resonance spectroscopy*

**MSIF.** *See Multidimensional Scale of Independent Functioning*

#### Multidimensional Scale of Independent Functioning

The Multidimensional Scale of Independent Functioning: A new instrument for measuring functional disability in psychiatric populations, 29(1):153-167, 2003

## N

**NAMHC.** *See National Advisory Mental Health Council*

#### National Adult Reading Test

Do people with schizophrenia comprehend what they read?, 29(3):499-507, 2003

#### National Advisory Mental Health Council

Approaches to multisite clinical trials: The National Institute of Mental Health perspective, 29(1):7-13, 2003

**National Institute of Mental Health.** *See also Clinical Antipsychotic Trials of Intervention Effectiveness project*

Approaches to multisite clinical trials: The National Institute of Mental Health perspective, 29(1):7-13, 2003

#### Near-infrared spectroscopy

Cerebrovascular response to cognitive tasks in patients with schizophrenia measured by near-infrared spectroscopy, 30(2):435-444, 2004

#### Needs assessment

Met and unmet needs of schizophrenia patients in a Spanish sample, 29(2):201-210, 2003

Needs-based planning for persons with schizophrenia residing in board-and-care homes, 30(1):123-132, 2004

When does experience of psychosis result in a need for care? A prospective general population study, 29(2):349-358, 2003

#### Negative symptoms

Add-on fluvoxamine improves primary negative symptoms: Evidence for specificity from response analysis of individual symptoms, 29(3):541-546, 2003

Aggregability of red blood cells of schizophrenia patients with negative syndrome is selectively enhanced, 30(4):913-922, 2004

Are negative symptoms associated with functioning deficits in both schizophrenia and nonschizo-

- phrenia patients? A 10-year longitudinal analysis, 30(4): 813-825, 2004
- Deficit versus negative syndrome in schizophrenia: Prediction of attentional impairment, 30(4): 827-835, 2004
- Duration of untreated psychosis and outcome of schizophrenia: Delay in intensive psychosocial treatment versus delay in treatment with antipsychotic medication, 29(2):341-348, 2003
- Early treatment-induced improvement of negative symptoms predicts cognitive functioning in treatment-naïve first episode schizophrenia: A 2-year followup, 30(4): 837-848, 2004
- Elevated levels of schizotypal features in parents of patients with a family history of schizophrenia spectrum disorders, 30(4):781-790, 2004
- Latent inhibition and overswitching in schizophrenia, 30(4): 713-726, 2004
- Left prefrontal repetitive transcranial magnetic stimulation in schizophrenia, 30(2):429-434, 2004
- Neuromotor functioning in adolescents with schizotypal personality disorder: Associations with symptoms and neurocognition, 29(2):285-298, 2003
- Premorbid functioning in schizophrenia: Relation to baseline symptoms, treatment response, and medication side effects, 30(2):265-278, 2004
- Schizophrenia, consciousness, and the self, 29(3):427-444, 2003
- The schizophrenia prodrome revisited: A neurodevelopmental perspective, 29(4):633-651, 2003
- A six-factor model of cognition in schizophrenia and related psychotic disorders: Relationships with clinical symptoms and functional capacity, 30(4): 739-754, 2004
- Which executive skills should we target to affect social functioning and symptom change? A study of a cognitive remediation therapy program, 30(1):87-100, 2004
- The Netherlands**
- Psychotic symptoms among male adolescent detainees in The Netherlands, 30(1):73-86, 2004
- Neuroanatomy**
- Cerebrovascular response to cognitive tasks in patients with schizophrenia measured by near-infrared spectroscopy, 30(2):435-444, 2004
- Increased nitric oxide radicals in postmortem brain from patients with schizophrenia, 30(4):923-934, 2004
- Left prefrontal repetitive transcranial magnetic stimulation in schizophrenia, 30(2):429-434, 2004
- Multiple structural brain measures obtained by three-dimensional magnetic resonance imaging to distinguish between schizophrenia patients and normal subjects, 30(2):393-404, 2004
- Orbitofrontal cortical dysfunction in akinetic catatonia: A functional magnetic resonance imaging study during negative emotional stimulation, 30(2):405-427, 2004
- Performance of schizophrenia patients on time-, event-, and activity-based prospective memory tasks, 30(4):693-701, 2004
- A review and new report of medial temporal lobe dysfunction as a vulnerability indicator for schizophrenia: A magnetic resonance imaging morphometric family study of the parahippocampal gyrus, 29(4):803-830, 2003
- What is the functional significance of hippocampal pathology in schizophrenia?, 30(2):367-392, 2004
- Neurodevelopment**
- Developmental pathology, dopamine, and stress: A model for the age of onset of schizophrenia symptoms, 30(4):875-900, 2004
- Discriminating value of total minor physical anomaly score on the Waldrop Physical Anomaly Scale between schizophrenia patients and normal control subjects, 30(2):361-366, 2004
- Early and late neurodevelopmental influences in the prodrome to schizophrenia: Contributions of genes, environment, and their interactions, 29(4):653-669, 2003
- Global intellectual impairment does not accelerate with age in patients with schizophrenia: A cross-sectional analysis, 29(3):509-517, 2003
- Neurodevelopmental interactions conferring risk for schizophrenia: A study of dermatoglyphic markers in patients and relatives, 29(3):595-605, 2003
- A review and new report of medial temporal lobe dysfunction as a vulnerability indicator for schizophrenia: A magnetic resonance imaging morphometric family study of the parahippocampal gyrus, 29(4):803-830, 2003
- The schizophrenia prodrome revisited: A neurodevelopmental perspective, 29(4):633-651, 2003
- Neuroendocrine system**
- What is the functional significance of hippocampal pathology in schizophrenia?, 30(2):367-392, 2004
- Neuroimaging**
- Cerebrovascular response to cognitive tasks in patients with schizophrenia measured by near-infrared spectroscopy, 30(2): 435-444, 2004
- Early and late neurodevelopmental influences in the prodrome to schizophrenia: Contributions of genes, environment, and their interactions, 29(4):653-669, 2003

- Left prefrontal repetitive transcranial magnetic stimulation in schizophrenia, 30(2):429-434, 2004
- Multiple structural brain measures obtained by three-dimensional magnetic resonance imaging to distinguish between schizophrenia patients and normal subjects, 30(2):393-404, 2004
- Overview of the First Annual Workshop on the Schizophrenia Prodrome, 29(4):625-631, 2003
- Proton magnetic resonance spectroscopy in first episode psychosis and ultra high-risk individuals, 29(4):831-843, 2003
- A review and new report of medial temporal lobe dysfunction as a vulnerability indicator for schizophrenia: A magnetic resonance imaging morphometric family study of the parahippocampal gyrus, 29(4):803-830, 2003
- Neuroleptic malignant syndrome**  
PORT treatment recommendations, 30(3):601-604, 2004
- Neuroleptics**  
Early treatment-induced improvement of negative symptoms predicts cognitive functioning in treatment-naïve first episode schizophrenia: A 2-year followup, 30(4):837-848, 2004
- Effectiveness of atypical antipsychotic medications in reducing violent behavior among persons with schizophrenia in community-based treatment, 30(1):3-20, 2004
- Sleep in untreated patients with schizophrenia: A meta-analysis, 30(4):957-967, 2004
- Stages of change in smokers with schizophrenia or schizoaffective disorder and in the general population, 30(2):459-468, 2004
- Study of sexuality-related characteristics in young adults with schizophrenia treated with novel neuroleptics and in a comparison group of young adults, 29(3):559-572, 2003
- Neurological soft signs**  
Neurological soft signs and their relationship to cognitive and clinical efficacy of atypical antipsychotics in schizophrenia, 30(2):241-253, 2004
- Neuromotor dysfunction**  
Neuromotor functioning in adolescents with schizotypal personality disorder: Associations with symptoms and neurocognition, 29(2):285-298, 2003
- Neuropsychology**  
Absence of additional cognitive impairment in schizophrenia patients during maintenance electroconvulsive therapy, 30(1):185-189, 2004
- Deficit versus negative syndrome in schizophrenia: Prediction of attentional impairment, 30(4):827-835, 2004
- Early treatment-induced improvement of negative symptoms predicts cognitive functioning in treatment-naïve first episode schizophrenia: A 2-year followup, 30(4):837-848, 2004
- Global intellectual impairment does not accelerate with age in patients with schizophrenia: A cross-sectional analysis, 29(3):509-517, 2003
- At issue: Sex and gender in schizophrenia, 30(4):755-762, 2004
- Neurocognitive assessment in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project schizophrenia trial: Development, methodology, and rationale, 29(1):45-55, 2003
- Prolonged untreated illness duration from prodromal onset predicts outcome in first episode psychoses, 29(4):757-769, 2003
- A review of cognitive training in schizophrenia, 29(2):359-382, 2003
- A six-factor model of cognition in schizophrenia and related psychotic disorders: Relationships with clinical symptoms and functional capacity, 30(4):739-754, 2004
- NHANES III.** See **Third National Health and Nutrition Examination Survey**
- Nicotine dependence.** See **Tobacco use**
- NIMH.** See **National Institute of Mental Health**
- NIRS.** See **Near-infrared spectroscopy**
- Nitric oxide**  
Increased nitric oxide radicals in postmortem brain from patients with schizophrenia, 30(4):923-934, 2004
- NMS.** See **Neuroleptic malignant syndrome**
- Northern Hemisphere**  
A systematic review and meta-analysis of Northern Hemisphere season of birth studies in schizophrenia, 29(3):587-593, 2003
- Nosology**  
The nosology of psychotic disorders: A comparison among competing classification systems, 29(3):413-425, 2003
- NSS.** See **Neurological soft signs**
- Nutrition**  
Nutritional assessment of patients with schizophrenia: A preliminary study, 29(2):393-397, 2003
- O**
- Obesity**  
Nutritional assessment of patients with schizophrenia: A preliminary study, 29(2):393-397, 2003
- Revised PORT recommendations, 30(3):609-611, 2004
- Weight gain with clozapine compared to first generation antipsychotic medications, 30(2):229-240, 2004
- Olanzapine**  
Estimating suicidality as outcome measure in clinical trials of suicide in schizophrenia, 30(3):587-598, 2004
- The International Suicide Prevention Trial (InterSePT): Rationale



and design of a trial comparing the relative ability of clozapine and olanzapine to reduce suicidal behavior in schizophrenia and schizoaffective patients, 30(3):577-586, 2004

The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: Schizophrenia trial design and protocol development, 29(1):15-31, 2003

Study of sexuality-related characteristics in young adults with schizophrenia treated with novel neuroleptics and in a comparison group of young adults, 29(3):559-572, 2003

#### **Omega-3 fatty acids**

Reduced red blood cell membrane essential polyunsaturated fatty acids in first episode schizophrenia at neuroleptic-naïve baseline, 30(4):901-911, 2004

#### **Omega-6 fatty acids**

Reduced red blood cell membrane essential polyunsaturated fatty acids in first episode schizophrenia at neuroleptic-naïve baseline, 30(4):901-911, 2004

#### **Outcome measures. See Course and outcome**

#### **Overswitching**

Latent inhibition and overswitching in schizophrenia, 30(4):713-726, 2004

## **P**

#### **PACE Clinic. See Personal Assessment and Crisis Evaluation Clinic**

#### **PANSS. See Positive and Negative Syndrome Scale**

#### **Paranoid personality disorder**

Offspring of parents with schizophrenia: Mental disorders during childhood and adolescence, 30(2):303-315, 2004

#### **Parkinsonism**

Premorbid functioning in schizophrenia: Relation to baseline symptoms, treatment response,

and medication side effects, 30(2):265-278, 2004

#### **PAS. See Premorbid Adjustment Scale**

#### **Patient satisfaction**

Satisfaction with mental health services among people with schizophrenia in five European sites: Results from the EPSILON study, 29(2):229-245, 2003

#### **PDI. See Peters et al. Delusions Inventory**

#### **Peculiarity**

Psychological trauma and schizotypal symptoms, 29(1):143-152, 2003

#### **Perphenazine**

The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: Schizophrenia trial design and protocol development, 29(1):15-31, 2003

#### **Personal Assessment and Crisis Evaluation Clinic**

The "close-in" or ultra high-risk model: A safe and effective strategy for research and clinical intervention in prepsychotic mental disorder, 29(4):771-790, 2003

Commentary: The schizophrenia prodrome: A high-risk concept, 29(4):859-865, 2003

#### **Personality dimensions**

Coping style in schizophrenia: Associations with neurocognitive deficits and personality, 30(1):113-121, 2004

#### **Personality disorders. See specific disorders, e.g., Antisocial personality disorder**

#### **Peters et al. Delusions Inventory**

Measuring delusional ideation: The 21-item Peters et al. Delusions Inventory (PDI), 30(4):1005-1022, 2004

#### **PHC. See Psychose hallucinatoire chronique**

#### **Physical anomalies. See Minor physical anomalies**

#### **Pickering, George**

The concept of population prevention: Application to schizophre-

nia, 29(4):791-801, 2003

#### **Platt, Robert**

The concept of population prevention: Application to schizophrenia, 29(4):791-801, 2003

#### **Poetry**

First person account: How insight poetry helped me to overcome my illness, 30(2):469-472, 2004

#### **Polyunsaturated fatty acids**

Reduced red blood cell membrane essential polyunsaturated fatty acids in first episode schizophrenia at neuroleptic-naïve baseline, 30(4):901-911, 2004

#### **PORT. See Schizophrenia Patient Outcomes Research Team**

#### **Positive and Negative Syndrome Scale**

Aggregability of red blood cells of schizophrenia patients with negative syndrome is selectively enhanced, 30(4):913-922, 2004

Are negative symptoms associated with functioning deficits in both schizophrenia and nonschizophrenia patients? A 10-year longitudinal analysis, 30(4):813-825, 2004

Five latent factors underlying schizophrenia: Analysis and relationship to illnesses in relatives, 30(4):855-873, 2004

The International Suicide Prevention Trial (InterSePT): Rationale and design of a trial comparing the relative ability of clozapine and olanzapine to reduce suicidal behavior in schizophrenia and schizoaffective patients, 30(3):577-586, 2004

At issue: Siblings of patients with schizophrenia: Sibling bond, coping patterns, and fear of possible schizophrenia heredity, 30(2):445-458, 2004

#### **Positive symptoms**

Aggregability of red blood cells of schizophrenia patients with negative syndrome is selectively enhanced, 30(4):913-922, 2004

- The assessment of "prodromal schizophrenia": Unresolved issues and future directions, 29(4):717-728, 2003
- Atypical antipsychotics in first admission schizophrenia: Medication continuation and outcomes, 29(3):519-530, 2003
- Clinical and etiopathogenic specificities of the French concept of *psychose hallucinatoire chronique* compared to schizophrenia, 30(1):173-184, 2004
- Developmental pathology, dopamine, and stress: A model for the age of onset of schizophrenia symptoms, 30(4):875-900, 2004
- Elevated levels of schizotypal features in parents of patients with a family history of schizophrenia spectrum disorders, 30(4):781-790, 2004
- Latent inhibition and overswitching in schizophrenia, 30(4):713-726, 2004
- Left prefrontal repetitive transcranial magnetic stimulation in schizophrenia, 30(2):429-434, 2004
- Schizophrenia, consciousness, and the self, 29(3):427-444, 2003
- The schizophrenia prodrome revisited: A neurodevelopmental perspective, 29(4):633-651, 2003
- Schizotypal personality traits in nonpsychotic relatives are associated with positive symptoms in psychotic probands, 29(2):273-283, 2003
- A six-factor model of cognition in schizophrenia and related psychotic disorders: Relationships with clinical symptoms and functional capacity, 30(4):739-754, 2004
- Which executive skills should we target to affect social functioning and symptom change? A study of a cognitive remediation therapy program, 30(1):87-100, 2004
- Postmortem studies**
- Increased nitric oxide radicals in postmortem brain from patients with schizophrenia, 30(4):923-934, 2004
- Posttraumatic stress disorder**
- Interpersonal trauma and posttraumatic stress disorder in patients with severe mental illness: Demographic, clinical, and health correlates, 30(1):45-57, 2004
- Prediction of psychosis**
- Commentary: The schizophrenia prodrome: A high-risk concept, 29(4):859-865, 2003
- Premorbid functioning in schizophrenia: Relation to baseline symptoms, treatment response, and medication side effects, 30(2):265-278, 2004
- Transition to schizophrenia and related disorders: Toward a taxonomy of risk, 29(4):693-701, 2003
- Pregnancy. See also Prenatal events**
- Assisted and surrogate decision making for pregnant patients who have schizophrenia, 30(3):659-664, 2004
- First person account: Schizophrenia and motherhood, 30(4):763-765, 2004
- Premorbid Adjustment Scale**
- Premorbid functioning in schizophrenia: Relation to baseline symptoms, treatment response, and medication side effects, 30(2):265-278, 2004
- Prolonged untreated illness duration from prodromal onset predicts outcome in first episode psychoses, 29(4):757-769, 2003
- Prenatal events. See also Pregnancy**
- Discriminating value of total minor physical anomaly score on the Waldrop Physical Anomaly Scale between schizophrenia patients and normal control subjects, 30(2):361-366, 2004
- Prescribing practices**
- Adherence of schizophrenia pharmacotherapy to published treatment recommendations: Patient, facility, and provider predictors, 30(3):649-658, 2004
- PORT treatment recommendations, 30(3):601-604, 2004
- Racial disparity in the pharmacological management of schizophrenia, 29(2):183-193, 2003
- Trends in the rate and type of antipsychotic medications prescribed to persons with schizophrenia, 29(3):531-540, 2003
- Validation of polypharmacy process measures in inpatient schizophrenia care, 30(4):1023-1033, 2004
- Present State Examination**
- At issue: A model for academic/industry collaboration, 30(4):992-1004, 2004
- Schizotypal personality traits in nonpsychotic relatives are associated with positive symptoms in psychotic probands, 29(2):273-283, 2003
- President's New Freedom Commission on Mental Health**
- Changing middle schoolers' attitudes about mental illness through education, 30(3):563-572, 2004
- Commentary: Service system perspectives on early intervention research, 29(4):867-875, 2003
- Half-full but nearly empty: Implications of the Schizophrenia PORT updated treatment recommendations, 30(3):619-621, 2004
- Updated Schizophrenia PORT treatment recommendations, 30(3):623-625, 2004
- Prevalence**
- The correlates of comorbid antisocial personality disorder in schizophrenia, 30(4):791-802, 2004
- Psychotic symptoms among male adolescent detainees in The Netherlands, 30(1):73-86, 2004
- Prevention efforts**
- The "close-in" or ultra high-risk model: A safe and effective strategy for research and clinical

- intervention in prepsychotic mental disorder, 29(4):771-790, 2003
- Commentary: Chickens and eggs; carts and horses: An outsider's perspective on the study of the early stages and potential prevention of psychosis and schizophrenia, 29(4):845-849, 2003
- The concept of population prevention: Application to schizophrenia, 29(4):791-801, 2003
- The correlates of comorbid antisocial personality disorder in schizophrenia, 30(4):791-802, 2004
- Overview of the First Annual Workshop on the Schizophrenia Prodrome, 29(4):625-631, 2003
- Prodromal assessment with the Structured Interview for Prodromal Syndromes and the Scale of Prodromal Symptoms: Predictive validity, interrater reliability, and training to reliability, 29(4):703-715, 2003
- The schizophrenia prodrome revisited: A neurodevelopmental perspective, 29(4):633-651, 2003
- Transition to schizophrenia and related disorders: Toward a taxonomy of risk, 29(4):693-701, 2003
- Treatment models and designs for intervention research during the psychotic prodrome, 29(4):747-756, 2003
- Prevention through Risk Identification, Management, and Education**
- Prodromal assessment with the Structured Interview for Prodromal Syndromes and the Scale of Prodromal Symptoms: Predictive validity, interrater reliability, and training to reliability, 29(4):703-715, 2003
- PRIME. See Prevention through Risk Identification, Management, and Education**
- Prolactin effects**
- Sexuality and schizophrenia: A review, 30(4):767-779, 2004
- Prospective memory. See Cognition**
- Prospective studies**
- The assessment of "prodromal schizophrenia": Unresolved issues and future directions, 29(4):717-728, 2003
- The International Suicide Prevention Trial (InterSePT): Rationale and design of a trial comparing the relative ability of clozapine and olanzapine to reduce suicidal behavior in schizophrenia and schizoaffective patients, 30(3):577-586, 2004
- Validation of polypharmacy process measures in inpatient schizophrenia care, 30(4):1023-1033, 2004
- When does experience of psychosis result in a need for care? A prospective general population study, 29(2):349-358, 2003
- Psychiatrists**
- What is ethically important in clinical research? A preliminary study of attitudes of 73 psychiatric faculty and residents, 29(3):607-613, 2003
- Psychoeducation**
- Changing middle schoolers' attitudes about mental illness through education, 30(3):563-572, 2004
- The effects of a documentary film about schizophrenia on psychiatric stigma, 29(2):383-391, 2003
- The Texas Medication Algorithm Project: Clinical results for schizophrenia, 30(3):627-647, 2004
- Psychopathology**
- Followup of psychotic outpatients: Dimensions of delusions and work functioning in schizophrenia, 30(1):147-161, 2004
- Investigating graphesthesia task performance in the biological relatives of schizophrenia patients, 30(2):327-334, 2004
- Met and unmet needs of schizophrenia patients in a Spanish sample, 29(2):201-210, 2003
- Neurological soft signs and their relationship to cognitive and clinical efficacy of atypical antipsychotics in schizophrenia, 30(2):241-253, 2004
- Schizophrenia, delusional symptoms, and violence: The threat/control-override concept reexamined, 30(1):31-44, 2004
- Psychose hallucinoire chronique**
- Clinical and etiopathogenic specificities of the French concept of psychose hallucinoire chronique compared to schizophrenia, 30(1):173-184, 2004
- Psychoses. See also First-episode psychosis; Mental illness; Prediction of psychosis**
- Age-at-first-registration for affective psychosis and schizophrenia, 30(4):849-853, 2004
- Are negative symptoms associated with functioning deficits in both schizophrenia and non-schizophrenia patients? A 10-year longitudinal analysis, 30(4):813-825, 2004
- Auditory hallucinations, source monitoring, and the belief that "voices" are real, 29(3):445-457, 2003
- Clinical and etiopathogenic specificities of the French concept of psychose hallucinoire chronique compared to schizophrenia, 30(1):173-184, 2004
- Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE): Alzheimer's disease trial, 29(1):57-72, 2003
- The "close-in" or ultra high-risk model: A safe and effective strategy for research and clinical intervention in prepsychotic mental disorder, 29(4):771-790, 2003
- Commentary: Chickens and eggs; carts and horses: An outsider's perspective on the study of the early stages and potential prevention of psychosis and schizophrenia, 29(4):845-849, 2003

- Commentary: Progress, issues, and implications of prodromal research: An inside view, 29(4):851-858, 2003
- Comorbid personality disorders and substance use disorders of mentally ill homicide offenders: A structured clinical study on dual and triple diagnoses, 30(1):59-72, 2004
- Correlates of the affective impact of auditory hallucinations in psychotic disorders, 30(1):163-171, 2004
- Duration of untreated psychosis and outcome of schizophrenia: Delay in intensive psychosocial treatment versus delay in treatment with antipsychotic medication, 29(2):341-348, 2003
- Five latent factors underlying schizophrenia: Analysis and relationship to illnesses in relatives, 30(4):855-873, 2004
- Followup of psychotic outpatients: Dimensions of delusions and work functioning in schizophrenia, 30(1):147-161, 2004
- The International Suicide Prevention Trial (InterSePT): Rationale and design of a trial comparing the relative ability of clozapine and olanzapine to reduce suicidal behavior in schizophrenia and schizoaffective patients, 30(3):577-586, 2004
- Interpersonal trauma and posttraumatic stress disorder in patients with severe mental illness: Demographic, clinical, and health correlates, 30(1):45-57, 2004
- The nosology of psychotic disorders: A comparison among competing classification systems, 29(3):413-425, 2003
- Orbitofrontal cortical dysfunction in akinetic catatonia: A functional magnetic resonance imaging study during negative emotional stimulation, 30(2):405-427, 2004
- Overcoming barriers to research in early serious mental illness: Issues for future collaboration, 29(4):737-745, 2003
- Psychotic motivation and the paradox of current research on serious mental illness and rates of violence, 30(1):21-30, 2004
- Psychotic symptoms among male adolescent detainees in The Netherlands, 30(1):73-86, 2004
- A randomized controlled trial of integrated versus parallel housing services for homeless adults with severe mental illness, 30(4):969-982, 2004
- Satisfaction with mental health services among people with schizophrenia in five European sites: Results from the EPSILON study, 29(2):229-245, 2003
- Sexuality and schizophrenia: A review, 30(4):767-779, 2004
- A six-factor model of cognition in schizophrenia and related psychotic disorders: Relationships with clinical symptoms and functional capacity, 30(4):739-754, 2004
- Treatment models and designs for intervention research during the psychotic prodrome, 29(4):747-756, 2003
- What is schizophrenic in acute and transient psychotic disorder?, 29(2):311-323, 2003
- What is the functional significance of hippocampal pathology in schizophrenia?, 30(2):367-392, 2004
- When does experience of psychosis result in a need for care? A prospective general population study, 29(2):349-358, 2003
- Psychosocial therapy**
- Duration of untreated psychosis and outcome of schizophrenia: Delay in intensive psychosocial treatment versus delay in treatment with antipsychotic medication, 29(2):341-348, 2003
- Inside the black box: The importance of monitoring treatment implementation, 30(3):613-615, 2004
- A review of cognitive training in schizophrenia, 29(2):359-382, 2003
- The Schizophrenia Patient Outcomes Research Team (PORT): Updated treatment recommendations 2003, 30(2):193-217, 2004
- Supportive therapy for schizophrenia: Possible mechanisms and implications for adjunctive psychosocial treatments, 30(1):101-112, 2004
- PTSD. See Posttraumatic stress disorder**
- Public mental health services**
- Age-at-first-registration for affective psychosis and schizophrenia, 30(4):849-853, 2004
- Commentary: Mental illness, society, stigma, and research, 30(3):573-575, 2004
- Commentary: Service system perspectives on early intervention research, 29(4):867-875, 2003
- Current and future forecasts of service use and expenditures of Medicaid-eligible schizophrenia patients in the state of Georgia, 30(4):983-995, 2004
- Direct costs of schizophrenia and related disorders in Italian community mental health services: A multicenter, prospective 1-year followup study, 30(2):295-302, 2004
- Effectiveness of atypical antipsychotic medications in reducing violent behavior among persons with schizophrenia in community-based treatment, 30(1):3-20, 2004
- Guest editors' introduction: What can large pragmatic clinical trials do for public mental health care?, 29(1):1-6, 2003
- Implementation of evidence-based practices in state mental health systems: Implications for research and effectiveness studies, 29(1):125-131, 2003
- Inside the black box: The importance of monitoring treatment implementation, 30(3):613-615, 2004



A randomized controlled trial of integrated versus parallel housing services for homeless adults with severe mental illness, 30(4):969-982, 2004

Trends in the rate and type of antipsychotic medications prescribed to persons with schizophrenia, 29(3):531-540, 2003

Weight gain with clozapine compared to first generation antipsychotic medications, 30(2):229-240, 2004

#### Public/private partnerships

At issue: A model for academic/industry collaboration, 30(4):992-1004, 2004

PUFAs. *See Polyunsaturated fatty acids*

## Q

#### Quality of care

Adherence of schizophrenia pharmacotherapy to published treatment recommendations: Patient, facility, and provider predictors, 30(3):649-658, 2004

Assisted and surrogate decision making for pregnant patients who have schizophrenia, 30(3):659-664, 2004

The diffusion of new antipsychotic medications and formulary policy, 29(1):95-104, 2003

Needs-based planning for persons with schizophrenia residing in board-and-care homes, 30(1):123-132, 2004

Satisfaction with mental health services among people with schizophrenia in five European sites: Results from the EPSILON study, 29(2):229-245, 2003

The Schizophrenia Care and Assessment Program Health Questionnaire (SCAP-HQ): An instrument to assess outcomes of schizophrenia care, 29(2):247-256, 2003

The Schizophrenia Patient Outcomes Research Team (PORT): Updated treatment recommen-

dations 2003, 30(2):193-217, 2004

Updated Schizophrenia PORT treatment recommendations, 30(3):623-625, 2004

Validation of polypharmacy process measures in inpatient schizophrenia care, 30(4):1023-1033, 2004

#### Quality of life

The disregarded caregivers: Subjective burden in spouses of schizophrenia patients, 30(3):665-675, 2004

Examining the factor structure of the Recovery Assessment Scale, 30(4):1035-1041, 2004

First person account: My dream life, a normal life, 30(4):1063-1065, 2004

Met and unmet needs of schizophrenia patients in a Spanish sample, 29(2):201-210, 2003

People with schizophrenia in five countries: Conceptual similarities and intercultural differences in family caregiving, 29(3):573-586, 2003

A randomized controlled trial of integrated versus parallel housing services for homeless adults with severe mental illness, 30(4):969-982, 2004

#### Questionnaires

Factorial composition of self-rated schizotypal traits among young males undergoing military training, 30(2):335-350, 2004

At issue: A model for academic/industry collaboration, 30(4):992-1004, 2004

Multiple dimensions of schizotypy in first degree biological relatives of schizophrenia patients, 30(2):317-325, 2004

People with schizophrenia in five countries: Conceptual similarities and intercultural differences in family caregiving, 29(3):573-586, 2003

The Schizophrenia Care and Assessment Program Health Questionnaire (SCAP-HQ): An

instrument to assess outcomes of schizophrenia care, 29(2):247-256, 2003

#### Quetiapine

The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: Schizophrenia trial design and protocol development, 29(1):15-31, 2003

## R

#### Racial factors. *See also Cultural factors*

Poor antipsychotic adherence among patients with schizophrenia: Medication and patient factors, 30(2):255-264, 2004

Racial disparity in the pharmacological management of schizophrenia, 29(2):183-193, 2003

Who are patients on conventional antipsychotics?, 29(2):195-199, 2003

#### Randomized controlled trials

Changing environments and alternative perspectives in evaluating the cost-effectiveness of new antipsychotic drugs, 29(1):81-93, 2003

Hallucination focused integrative treatment: A randomized controlled trial, 30(1):133-145, 2004

Left prefrontal repetitive transcranial magnetic stimulation in schizophrenia, 30(2):429-434, 2004

A randomized controlled trial of integrated versus parallel housing services for homeless adults with severe mental illness, 30(4):969-982, 2004

Randomized controlled trials in evidence-based mental health care: Getting the right answer to the right question, 29(1):115-123, 2003

A review of cognitive training in schizophrenia, 29(2):359-382, 2003

Which executive skills should we target to affect social functioning and symptom change? A study of a cognitive remediation therapy program, 30(1):87-100, 2004

**RAP program.** See **Recognition and Prevention program**

**RAS.** See **Recovery Assessment Scale**

**RCBA.** See **Reading Comprehension Battery for Aphasia**

**rCBF.** See **Regional cerebral blood flow**

**Reading Comprehension Battery for Aphasia**

Do people with schizophrenia comprehend what they read?, 29(3):499-507, 2003

**Recognition and Prevention program**

The assessment of "prodromal schizophrenia": Unresolved issues and future directions, 29(4):717-728, 2003

The schizophrenia prodrome revisited: A neurodevelopmental perspective, 29(4):633-651, 2003

**Recovery Assessment Scale**

Examining the factor structure of the Recovery Assessment Scale, 30(4):1035-1041, 2004

**Red blood cells**

Aggregability of red blood cells of schizophrenia patients with negative syndrome is selectively enhanced, 30(4):913-922, 2004

Reduced red blood cell membrane essential polyunsaturated fatty acids in first episode schizophrenia at neuroleptic-naïve baseline, 30(4):901-911, 2004

**Regional cerebral blood flow**

Aggregability of red blood cells of schizophrenia patients with negative syndrome is selectively enhanced, 30(4):913-922, 2004

**Regression analyses**

Examining the factor structure of the Recovery Assessment Scale, 30(4):1035-1041, 2004

At issue: Sex and gender in schizophrenia, 30(4):755-762, 2004

The role of attention in affect perception: An examination of Mirsky's four factor model of attention in chronic schizophrenia, 30(4):727-738, 2004

**Rehabilitation**

Coping style in schizophrenia: Associations with neurocognitive deficits and personality, 30(1):113-121, 2004

Disease management in Latinos with schizophrenia: A family-assisted, skills training approach, 29(2):211-227, 2003

Is emotion processing a predictor of functional outcome in schizophrenia?, 29(3):487-497, 2003

At issue: The future of cognitive rehabilitation of schizophrenia, 30(4):679-692, 2004

Performance of schizophrenia patients on time-, event-, and activity-based prospective memory tasks, 30(4):693-701, 2004

A review of cognitive training in schizophrenia, 29(2):359-382, 2003

**Rehospitalization**

Atypical antipsychotics in first admission schizophrenia: Medication continuation and outcomes, 29(3):519-530, 2003

Duration of untreated psychosis and outcome of schizophrenia: Delay in intensive psychosocial treatment versus delay in treatment with antipsychotic medication, 29(2):341-348, 2003

Followup of psychotic outpatients: Dimensions of delusions and work functioning in schizophrenia, 30(1):147-161, 2004

People with schizophrenia in five countries: Conceptual similarities and intercultural differences in family caregiving, 29(3):573-586, 2003

**Repetitive transcranial magnetic stimulation**

Left prefrontal repetitive transcranial magnetic stimulation in schizophrenia, 30(2):429-434, 2004

**Report on Mental Illness**

Half-full but nearly empty: Implications of the Schizophrenia PORT updated treatment recommendations, 30(3):619-621, 2004

Updated Schizophrenia PORT treatment recommendations, 30(3):623-625, 2004

**Research methodology**

The "close-in" or ultra high-risk model: A safe and effective strategy for research and clinical intervention in prepsychotic mental disorder, 29(4):771-790, 2003

Commentary: Progress, issues, and implications of prodromal research: An inside view, 29(4):851-858, 2003

Images of mental illness in the media: Identifying gaps in the research, 30(3):543-561, 2004

The International Suicide Prevention Trial (InterSePT): Rationale and design of a trial comparing the relative ability of clozapine and olanzapine to reduce suicidal behavior in schizophrenia and schizoaffective patients, 30(3):577-586, 2004

Measuring mental illness stigma, 30(3):511-541, 2004

Overcoming barriers to research in early serious mental illness: Issues for future collaboration, 29(4):737-745, 2003

Treatment models and designs for intervention research during the psychotic prodrome, 29(4):747-756, 2003

**Residential care**

Needs-based planning for persons with schizophrenia residing in board-and-care homes, 30(1):123-132, 2004

A randomized controlled trial of integrated versus parallel housing services for homeless adults with severe mental illness, 30(4):969-982, 2004

**Response analyses**

Add-on fluvoxamine improves primary negative symptoms:

Evidence for specificity from response analysis of individual symptoms, 29(3):541-546, 2003

#### **Risk adjustment**

Risk adjustment in studies using administrative data, 29(2):267-271, 2003

#### **Risk factors. See also Vulnerability factors**

The assessment of "prodromal schizophrenia": Unresolved issues and future directions, 29(4):717-728, 2003

The "close-in" or ultra high-risk model: A safe and effective strategy for research and clinical intervention in prepsychotic mental disorder, 29(4):771-790, 2003

Commentary: The schizophrenia prodrome: A high-risk concept, 29(4):859-865, 2003

The concept of population prevention: Application to schizophrenia, 29(4):791-801, 2003

The correlates of comorbid antisocial personality disorder in schizophrenia, 30(4):791-802, 2004

Early and late neurodevelopmental influences in the prodrome to schizophrenia: Contributions of genes, environment, and their interactions, 29(4):653-669, 2003

Elevated levels of schizotypal features in parents of patients with a family history of schizophrenia spectrum disorders, 30(4):781-790, 2004

Five latent factors underlying schizophrenia: Analysis and relationship to illnesses in relatives, 30(4):855-873, 2004

Offspring of parents with schizophrenia: Mental disorders during childhood and adolescence, 30(2):303-315, 2004

Overcoming barriers to research in early serious mental illness: Issues for future collaboration, 29(4):737-745, 2003

Overview of the First Annual Workshop on the Schizophrenia Prodrome, 29(4):625-631, 2003

Proton magnetic resonance spectroscopy in first episode psychosis and ultra high-risk individuals, 29(4):831-843, 2003

The schizophrenia prodrome revisited: A neurodevelopmental perspective, 29(4):633-651, 2003

The stress cascade and schizophrenia: Etiology and onset, 29(4):671-692, 2003

Suicide in schizophrenia: The Wessex Recent Inpatient Suicide Study: A retrospective case-control study of 51 suicides, 30(4):803-811, 2004

Transition to schizophrenia and related disorders: Toward a taxonomy of risk, 29(4):693-701, 2003

Using neurophysiological markers of genetic risk to define the boundaries of the schizophrenia spectrum phenotype, 29(2):299-309, 2003

#### **Risperidone**

The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: Schizophrenia trial design and protocol development, 29(1):15-31, 2003

Study of sexuality-related characteristics in young adults with schizophrenia treated with novel neuroleptics and in a comparison group of young adults, 29(3):559-572, 2003

**rTMS. See Repetitive transcranial magnetic stimulation**

## **S**

**SANS. See Scale for the Assessment of Negative Symptoms**

**SAPS. See Scale for the Assessment of Positive Symptoms**

**SAS II. See Social Adjustment Scale II**

#### **Scale for the Assessment of Negative Symptoms**

Add-on fluvoxamine improves primary negative symptoms: Evidence for specificity from response analysis of individual symptoms, 29(3):541-546, 2003

Five latent factors underlying schizophrenia: Analysis and relationship to illnesses in relatives, 30(4):855-873, 2004

#### **Scale for the Assessment of Positive Symptoms**

Five latent factors underlying schizophrenia: Analysis and relationship to illnesses in relatives, 30(4):855-873, 2004

#### **Scale of Prodromal Symptoms**

The assessment of "prodromal schizophrenia": Unresolved issues and future directions, 29(4):717-728, 2003

Prodromal assessment with the Structured Interview for Prodromal Syndromes and the Scale of Prodromal Symptoms: Predictive validity, interrater reliability, and training to reliability, 29(4):703-715, 2003

#### **SCAP-HQ. See Schizophrenia Care and Assessment Program Health Questionnaire**

#### **Schedule for the Deficit Syndrome**

Five latent factors underlying schizophrenia: Analysis and relationship to illnesses in relatives, 30(4):855-873, 2004

#### **Schizoaffective disorder**

Alcohol consumption and the CAGE test in outpatients with schizophrenia or schizoaffective disorder and in the general population, 30(4):947-956, 2004

Are negative symptoms associated with functioning deficits in both schizophrenia and non-schizophrenia patients? A 10-year longitudinal analysis, 30(4):813-825, 2004

Direct costs of schizophrenia and related disorders in Italian community mental health services: A multicenter, prospective 1-year

followup study, 30(2):295-302, 2004

First person account: Schizoaffective disorder and suicide, 30(3):677, 2004

Five latent factors underlying schizophrenia: Analysis and relationship to illnesses in relatives, 30(4):855-873, 2004

The influence of a working memory load manipulation on language production in schizophrenia, 29(3):473-485, 2003

The International Suicide Prevention Trial (InterSePT): Rationale and design of a trial comparing the relative ability of clozapine and olanzapine to reduce suicidal behavior in schizophrenia and schizoaffective patients, 30(3):577-586, 2004

At issue: Sex and gender in schizophrenia, 30(4):755-762, 2004

At issue: Will the term brain disease reduce stigma and promote parity for mental illnesses?, 30(4):1043-1048, 2004

Poor antipsychotic adherence among patients with schizophrenia: Medication and patient factors, 30(2):255-264, 2004

Premorbid functioning in schizophrenia: Relation to baseline symptoms, treatment response, and medication side effects, 30(2):265-278, 2004

Reduced red blood cell membrane essential polyunsaturated fatty acids in first episode schizophrenia at neuroleptic-naïve baseline, 30(4):901-911, 2004

Stages of change in smokers with schizophrenia or schizoaffective disorder and in the general population, 30(2):459-468, 2004

#### Schizophrenia

Assessing clinical and functional outcomes in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial, 29(1):33-43, 2003

The National Institute of Mental Health Clinical Antipsychotic

Trials of Intervention Effectiveness (CATIE) project: Schizophrenia trial design and protocol development, 29(1):15-31, 2003

Neurocognitive assessment in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project schizophrenia trial: Development, methodology, and rationale, 29(1):45-55, 2003

Statistical approaches to effectiveness measurement and outcome-driven re-randomizations in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) studies, 29(1):73-80, 2003

#### Schizophrenia Care and Assessment Program Health Questionnaire

The Schizophrenia Care and Assessment Program Health Questionnaire (SCAP-HQ): An instrument to assess outcomes of schizophrenia care, 29(2):247-256, 2003

#### Schizophrenia Patient Outcomes Research Team. See also Course and outcome

Adherence of schizophrenia pharmacotherapy to published treatment recommendations: Patient, facility, and provider predictors, 30(3):649-658, 2004

Half-full but nearly empty: Implications of the Schizophrenia PORT updated treatment recommendations, 30(3):619-621, 2004

Inside the black box: The importance of monitoring treatment implementation, 30(3):613-615, 2004

PORT recommendations, 30(3):605-607, 2004

PORT treatment recommendations, 30(3):601-604, 2004

PORT updated treatment recommendations, 30(3):617-618, 2004

Racial disparity in the pharmacological management of schizophrenia, 29(2):183-193, 2003

Revised PORT recommendations, 30(3):609-611, 2004

The Schizophrenia Patient Outcomes Research Team (PORT): Updated treatment recommendations 2003, 30(2):193-217, 2004

Updated Schizophrenia PORT treatment recommendations, 30(3):623-625, 2004

#### Schizophrenia spectrum disorders.

*See also specific disorders*

Coping style in schizophrenia: Associations with neurocognitive deficits and personality, 30(1):113-121, 2004

Effectiveness of atypical antipsychotic medications in reducing violent behavior among persons with schizophrenia in community-based treatment, 30(1):3-20, 2004

Elevated levels of schizotypal features in parents of patients with a family history of schizophrenia spectrum disorders, 30(4):781-790, 2004

Needs-based planning for persons with schizophrenia residing in board-and-care homes, 30(1):123-132, 2004

#### Schizophrenia spectrum personality disorders

Using neurophysiological markers of genetic risk to define the boundaries of the schizophrenia spectrum phenotype, 29(2):299-309, 2003

#### Schizophreniform disorder

Direct costs of schizophrenia and related disorders in Italian community mental health services: A multicenter, prospective 1-year followup study, 30(2):295-302, 2004

#### Schizotypal personality disorder

Factorial composition of self-rated schizotypal traits among young males undergoing military training, 30(2):335-350, 2004

Neuromotor functioning in adolescents with schizotypal personality disorder: Associations with



- symptoms and neurocognition, 29(2):285-298, 2003
- Offspring of parents with schizophrenia: Mental disorders during childhood and adolescence, 30(2):303-315, 2004
- Schizotypal personality traits in nonpsychotic relatives are associated with positive symptoms in psychotic probands, 29(2):273-283, 2003
- Schizotypal Personality Questionnaire**
- Elevated levels of schizotypal features in parents of patients with a family history of schizophrenia spectrum disorders, 30(4):781-790, 2004
- Factorial composition of self-rated schizotypal traits among young males undergoing military training, 30(2):335-350, 2004
- Multiple dimensions of schizotypy in first degree biological relatives of schizophrenia patients, 30(2):317-325, 2004
- Schizotypy**
- Elevated levels of schizotypal features in parents of patients with a family history of schizophrenia spectrum disorders, 30(4):781-790, 2004
- Factorial composition of self-rated schizotypal traits among young males undergoing military training, 30(2):335-350, 2004
- Investigating graphesthesia task performance in the biological relatives of schizophrenia patients, 30(2):327-334, 2004
- At issue: A model for academic/industry collaboration, 30(4):992-1004, 2004
- Multiple dimensions of schizotypy in first degree biological relatives of schizophrenia patients, 30(2):317-325, 2004
- Psychological trauma and schizotypal symptoms, 29(1):143-152, 2003
- Science education**
- Changing middle schoolers' attitudes about mental illness through education, 30(3):563-572, 2004
- Seasonal factors**
- A systematic review and meta-analysis of Northern Hemisphere season of birth studies in schizophrenia, 29(3):587-593, 2003
- Selective serotonin reuptake inhibitors**
- Add-on fluvoxamine improves primary negative symptoms: Evidence for specificity from response analysis of individual symptoms, 29(3):541-546, 2003
- Service satisfaction. See Patient satisfaction**
- Sex factors. See also Gender factors**
- At issue: Sex and gender in schizophrenia, 30(4):755-762, 2004
- Sexual functioning**
- Sexuality and schizophrenia: A review, 30(4):767-779, 2004
- Study of sexuality-related characteristics in young adults with schizophrenia treated with novel neuroleptics and in a comparison group of young adults, 29(3):559-572, 2003
- Sibling studies. See also Family studies; Twin studies**
- At issue: Siblings of patients with schizophrenia: Sibling bond, coping patterns, and fear of possible schizophrenia heredity, 30(2):445-458, 2004
- Side effects. See also Adverse effects; Extrapyramidal side effects**
- Adherence of schizophrenia pharmacotherapy to published treatment recommendations: Patient, facility, and provider predictors, 30(3):649-658, 2004
- SIPS. See Structured Interview for Prodromal Syndromes**
- Skills training. See Social skills training**
- Sleep studies**
- Sleep in untreated patients with schizophrenia: A meta-analysis, 30(4):957-967, 2004
- SMB. See Suicide Monitoring Board**
- SMF. See Source Monitoring Framework**
- Smoking. See Tobacco use**
- Social Adjustment Scale II**
- The Multidimensional Scale of Independent Functioning: A new instrument for measuring functional disability in psychiatric populations, 29(1):153-167, 2003
- Social factors. See also Cultural factors**
- Modeling the early course of schizophrenia, 29(2):325-340, 2003
- Social functioning. See also Functional impairment**
- Are negative symptoms associated with functioning deficits in both schizophrenia and non-schizophrenia patients? A 10-year longitudinal analysis, 30(4):813-825, 2004
- Hallucination focused integrative treatment: A randomized controlled trial, 30(1):133-145, 2004
- Is emotion processing a predictor of functional outcome in schizophrenia?, 29(3):487-497, 2003
- The role of attention in affect perception: An examination of Mirsky's four factor model of attention in chronic schizophrenia, 30(4):727-738, 2004
- Validation of polypharmacy process measures in inpatient schizophrenia care, 30(4):1023-1033, 2004
- Which executive skills should we target to affect social functioning and symptom change? A study of a cognitive remediation therapy program, 30(1):87-100, 2004
- Social skills training**
- Disease management in Latinos with schizophrenia: A family-assisted, skills training approach, 29(2):211-227, 2003
- Somatosensory system**
- Investigating graphesthesia task performance in the biological

relatives of schizophrenia patients, 30(2):327-334, 2004

**SOPS. See Scale of Prodromal Symptoms**

**Source Monitoring Framework**

Auditory hallucinations, source monitoring, and the belief that "voices" are real, 29(3): 445-457, 2003

**Spain**

Caffeine intake in outpatients with schizophrenia, 30(4):935-945, 2004

Met and unmet needs of schizophrenia patients in a Spanish sample, 29(2):201-210, 2003

**SPD. See Schizotypal personality disorder**

**Spouses of patients**

The disregarded caregivers: Subjective burden in spouses of schizophrenia patients, 30(3): 665-675, 2004

**SPQ. See Schizotypal Personality Questionnaire**

**SSP disorders. See Schizophrenia spectrum personality disorders**

**SSRIs. See Selective serotonin reuptake inhibitors**

**ST. See Supportive therapy**

**Statistical models**

Statistical approaches to effectiveness measurement and outcome-driven re-randomizations in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) studies, 29(1):73-80, 2003

**Stereotypes**

The stereotype of schizophrenia and its impact on discrimination against people with schizophrenia: Results from a representative survey in Germany, 30(4):1049-1061, 2004

**Stigma**

Changing middle schoolers' attitudes about mental illness through education, 30(3): 563-572, 2004

Commentary: Mental illness, society, stigma, and research, 30(3):573-575, 2004

Editors' introduction: Building mental illness stigma research, 30(3):473-475, 2004

The effects of a documentary film about schizophrenia on psychiatric stigma, 29(2):383-391, 2003

First person account: Schizophrenia and motherhood, 30(4): 763-765, 2004

Images of mental illness in the media: Identifying gaps in the research, 30(3):543-561, 2004

At issue: Stop the stigma: Call mental illness a brain disease, 30(3):477-479, 2004

At issue: Will the term brain disease reduce stigma and promote parity for mental illnesses?, 30(4):1043-1048, 2004

Measuring mental illness stigma, 30(3):511-541, 2004

The stereotype of schizophrenia and its impact on discrimination against people with schizophrenia: Results from a representative survey in Germany, 30(4): 1049-1061, 2004

From stigma to discrimination: An analysis of community efforts to reduce the negative consequences of having a psychiatric disorder and label, 30(3): 493-509, 2004

Structural levels of mental illness stigma and discrimination, 30(3):481-491, 2004

**Strauss and Carpenter Outcome Scale**

Is emotion processing a predictor of functional outcome in schizophrenia?, 29(3):487-497, 2003

Prolonged untreated illness duration from prodromal onset predicts outcome in first episode psychoses, 29(4):757-769, 2003

**Stress. See also Posttraumatic stress disorder**

Coping style in schizophrenia: Associations with neurocognitive deficits and personality, 30(1):113-121, 2004

Developmental pathology, dopamine, and stress: A model for the age of onset of schizophrenia symptoms, 30(4):875-900, 2004

Psychological trauma and schizotypal symptoms, 29(1):143-152, 2003

The stress cascade and schizophrenia: Etiology and onset, 29(4):671-692, 2003

What is the functional significance of hippocampal pathology in schizophrenia?, 30(2):367-392, 2004

**Stroop Color-Word Test**

Dynamic testing in schizophrenia: Does training change the construct validity of a test?, 30(4):703-711, 2004

**Structured Clinical Interview**

Comorbid personality disorders and substance use disorders of mentally ill homicide offenders: A structured clinical study on dual and triple diagnoses, 30(1):59-72, 2004

**Structured Interview for Prodromal Syndromes**

Creating school-age versions of semistructured interviews for the prodrome to schizophrenia: Lessons from case reviews, 29(4):729-735, 2003

Prodromal assessment with the Structured Interview for Prodromal Syndromes and the Scale of Prodromal Symptoms: Predictive validity, interrater reliability, and training to reliability, 29(4):703-715, 2003

**Subjective experiences**

First person account: How insight poetry helped me to overcome my illness, 30(2):469-472, 2004

First person account: Living with the delusions and effects of schizophrenia, 29(4):877-879, 2003

First person account: Medicines are not enough, 29(1):139-142, 2003

First person account: My dream life, a normal life, 30(4):1063–1065, 2004

First person account: Schizoaffective disorder and suicide, 30(3):677, 2004

First person account: Schizophrenia and motherhood, 30(4):763–765, 2004

First person account: The best medicine, 29(3):615–616, 2003

First person account: The clogs, 30(1):191–192

Home sweet home, 29(2):399–400, 2003

#### **Substance abuse**

Comorbid personality disorders and substance use disorders of mentally ill homicide offenders: A structured clinical study on dual and triple diagnoses, 30(1):59–72, 2004

The correlates of comorbid antisocial personality disorder in schizophrenia, 30(4):791–802, 2004

Effectiveness of atypical antipsychotic medications in reducing violent behavior among persons with schizophrenia in community-based treatment, 30(1):3–20, 2004

Interpersonal trauma and posttraumatic stress disorder in patients with severe mental illness: Demographic, clinical, and health correlates, 30(1):45–57, 2004

Schizophrenia, delusional symptoms, and violence: The threat/control-override concept reexamined, 30(1):31–44, 2004

Who are patients on conventional antipsychotics?, 29(2):195–199, 2003

#### **Suffolk County Mental Health Project**

Atypical antipsychotics in first admission schizophrenia: Medication continuation and outcomes, 29(3):519–530, 2003

#### **Suicide**

Estimating suicidality as outcome measure in clinical trials of sui-

cide in schizophrenia, 30(3):587–598, 2004

First person account: Schizoaffective disorder and suicide, 30(3):677, 2004

The International Suicide Prevention Trial (InterSePT): Rationale and design of a trial comparing the relative ability of clozapine and olanzapine to reduce suicidal behavior in schizophrenia and schizoaffective patients, 30(3):577–586, 2004

Suicide in schizophrenia: The Wessex Recent Inpatient Suicide Study: A retrospective case-control study of 51 suicides, 30(4):803–811, 2004

#### **Suicide Monitoring Board**

Estimating suicidality as outcome measure in clinical trials of suicide in schizophrenia, 30(3):587–598, 2004

#### **Supportive therapy**

Supportive therapy for schizophrenia: Possible mechanisms and implications for adjunctive psychosocial treatments, 30(1):101–112, 2004

#### **Switzerland**

Alcohol consumption and the CAGE test in outpatients with schizophrenia or schizoaffective disorder and in the general population, 30(4):947–956, 2004

Stages of change in smokers with schizophrenia or schizoaffective disorder and in the general population, 30(2):459–468, 2004

## **T**

#### **Tardive dyskinesia**

PORT treatment recommendations, 30(3):601–604, 2004

Revised PORT recommendations, 30(3):609–611, 2004

#### **Taxonomy**

Transition to schizophrenia and related disorders: Toward a taxonomy of risk, 29(4):693–701, 2003

**TD.** See **Tardive dyskinesia**

#### **Terminology**

At issue: Will the term brain disease reduce stigma and promote parity for mental illnesses?, 30(4):1043–1048, 2004

#### **Texas Medication Algorithm Project**

PORT treatment recommendations, 30(3):601–604, 2004

The Texas Medication Algorithm Project: Clinical results for schizophrenia, 30(3):627–647, 2004

#### **Third National Health and Nutrition Examination Survey**

Nutritional assessment of patients with schizophrenia: A preliminary study, 29(2):393–397, 2003

#### **Thought disorder**

The cognitive basis of disorganization symptomatology in schizophrenia and its clinical correlates: Toward a pathogenetic approach to disorganization, 29(3):459–471, 2003

The influence of a working memory load manipulation on language production in schizophrenia, 29(3):473–485, 2003

#### **Threat/control-override concept**

Schizophrenia, delusional symptoms, and violence: The threat/control-override concept reexamined, 30(1):31–44, 2004

#### **TMAP.** See **Texas Medication Algorithm Project**

#### **Tobacco use**

Caffeine intake in outpatients with schizophrenia, 30(4):935–945, 2004

Stages of change in smokers with schizophrenia or schizoaffective disorder and in the general population, 30(2):459–468, 2004

#### **TOL.** See **Tower of London**

#### **Tower of Hanoi**

Dynamic testing in schizophrenia: Does training change the construct validity of a test?, 30(4):703–711, 2004

#### **Tower of London**

Performance of schizophrenia patients on time-, event-, and

activity-based prospective memory tasks, 30(4):693–701, 2004

**Trauma.** *See also Posttraumatic stress disorder; Stress*

Interpersonal trauma and posttraumatic stress disorder in patients with severe mental illness: Demographic, clinical, and health correlates, 30(1):45–57, 2004

Psychological trauma and schizotypal symptoms, 29(1):143–152, 2003

**Treatment studies**

Add-on fluvoxamine improves primary negative symptoms: Evidence for specificity from response analysis of individual symptoms, 29(3):541–546, 2003

Adherence of schizophrenia pharmacotherapy to published treatment recommendations: Patient, facility, and provider predictors, 30(3):649–658, 2004

Commentary: Progress, issues, and implications of prodromal research: An inside view, 29(4):851–858, 2003

The correlates of comorbid antisocial personality disorder in schizophrenia, 30(4):791–802, 2004

The diffusion of new antipsychotic medications and formulary policy, 29(1):95–104, 2003

Early treatment-induced improvement of negative symptoms predicts cognitive functioning in treatment-naïve first episode schizophrenia: A 2-year followup, 30(4):837–848, 2004

Half-full but nearly empty: Implications of the Schizophrenia PORT updated treatment recommendations, 30(3):619–621, 2004

Hallucination focused integrative treatment: A randomized controlled trial, 30(1):133–145, 2004

Inside the black box: The importance of monitoring treatment

implementation, 30(3):613–615, 2004

At issue: The future of cognitive rehabilitation of schizophrenia, 30(4):679–692, 2004

Neurological soft signs and their relationship to cognitive and clinical efficacy of atypical antipsychotics in schizophrenia, 30(2):241–253, 2004

PORT recommendations, 30(3):605–607, 2004

PORT treatment recommendations, 30(3):601–604, 2004

PORT updated treatment recommendations, 30(3):617–618, 2004

Preference weights for cost-outcome analyses of schizophrenia treatments: Comparison of four stakeholder groups, 29(2):257–266, 2003

Revised PORT recommendations, 30(3):609–611, 2004

Risk adjustment in studies using administrative data, 29(2):267–271, 2003

The Schizophrenia Patient Outcomes Research Team (PORT): Updated treatment recommendations 2003, 30(2):193–217, 2004

Science to services: Consumers need “real world” science, 29(1):133–137, 2003

The Texas Medication Algorithm Project: Clinical results for schizophrenia, 30(3):627–647, 2004

Treatment models and designs for intervention research during the psychotic prodrome, 29(4):747–756, 2003

Updated Schizophrenia PORT treatment recommendations, 30(3):623–625, 2004

Which executive skills should we target to affect social functioning and symptom change? A study of a cognitive remediation therapy program, 30(1):87–100, 2004

Who are patients on conventional antipsychotics?, 29(2):195–199, 2003

**Twin studies.** *See also Sibling studies*

Monozygotic twins exhibit numerous epigenetic differences: Clues to twin discordance?, 29(1):169–178, 2003

**“Two-hit” hypothesis**

Neurodevelopmental interactions conferring risk for schizophrenia: A study of dermatoglyphic markers in patients and relatives, 29(3):595–605, 2003

**V**

**VA.** *See Department of Veterans Affairs*

**Verbal fluency test**

Cerebrovascular response to cognitive tasks in patients with schizophrenia measured by near-infrared spectroscopy, 30(2):435–444, 2004

**Verbal IQ Test**

Dynamic testing in schizophrenia: Does training change the construct validity of a test?, 30(4):703–711, 2004

**Verona Service Satisfaction Scale**

Satisfaction with mental health services among people with schizophrenia in five European sites: Results from the EPSILON study, 29(2):229–245, 2003

**VF.** *See Verbal fluency test*

**Violence.** *See also Criminal behavior*

Comorbid personality disorders and substance use disorders of mentally ill homicide offenders: A structured clinical study on dual and triple diagnoses, 30(1):59–72, 2004

The correlates of comorbid antisocial personality disorder in schizophrenia, 30(4):791–802, 2004

Effectiveness of atypical antipsychotic medications in reducing violent behavior among persons with schizophrenia in community-based treatment, 30(1):3–20, 2004



Psychotic motivation and the paradox of current research on serious mental illness and rates of violence, 30(1):21–30, 2004

Psychotic symptoms among male adolescent detainees in The Netherlands, 30(1):73–86, 2004

Schizophrenia, delusional symptoms, and violence: The threat/control-override concept reexamined, 30(1):31–44, 2004

**Vulnerability factors. See also Risk factors**

Earlier age of first diagnosis in schizophrenia is related to impaired motor control, 30(2):351–360, 2004

Elevated levels of schizotypal features in parents of patients with a family history of schizophrenia spectrum disorders, 30(4):781–790, 2004

At issue: Siblings of patients with schizophrenia: Sibling bond, coping patterns, and fear of possible schizophrenia heredity, 30(2):445–458, 2004

At issue: The future of cognitive rehabilitation of schizophrenia, 30(4):679–692, 2004

Neurodevelopmental interactions conferring risk for schizophrenia: A study of dermatoglyphic markers in patients and relatives, 29(3):595–605, 2003

Offspring of parents with schizophrenia: Mental disorders during childhood and adolescence, 30(2):303–315, 2004

Overview of the First Annual Workshop on the Schizophrenia Prodrome, 29(4):625–631, 2003

A review and new report of medial temporal lobe dysfunction as a vulnerability indicator

for schizophrenia: A magnetic resonance imaging morphometric family study of the parahippocampal gyrus, 29(4):803–830, 2003

The schizophrenia prodrome revisited: A neurodevelopmental perspective, 29(4):633–651, 2003

The stress cascade and schizophrenia: Etiology and onset, 29(4):671–692, 2003

Suicide in schizophrenia: The Wessex Recent Inpatient Suicide Study: A retrospective case-control study of 51 suicides, 30(4):803–811, 2004

Transition to schizophrenia and related disorders: Toward a taxonomy of risk, 29(4):693–701, 2003

What is the functional significance of hippocampal pathology in schizophrenia?, 30(2):367–392, 2004

**W**

**Waldrop Physical Anomaly Scale**

Discriminating value of total minor physical anomaly score on the Waldrop Physical Anomaly Scale between schizophrenia patients and normal control subjects, 30(2):361–366, 2004

**WCST. See Wisconsin Card Sorting Test**

**Wechsler Adult Intelligence Scale**

Global intellectual impairment does not accelerate with age in patients with schizophrenia: A cross-sectional analysis, 29(3):509–517, 2003

**Weight gain. See also Obesity**

Weight gain with clozapine compared to first generation antipsychotic medications, 30(2):229–240, 2004

**Wessex Recent Inpatient Suicide Study**

Suicide in schizophrenia: The Wessex Recent Inpatient Suicide Study: A retrospective case-control study of 51 suicides, 30(4):803–811, 2004

**Wisconsin Card Sorting Test**

Deficit versus negative syndrome in schizophrenia: Prediction of attentional impairment, 30(4):827–835, 2004

Dynamic testing in schizophrenia: Does training change the construct validity of a test?, 30(4):703–711, 2004

Performance of schizophrenia patients on time-, event-, and activity-based prospective memory tasks, 30(4):693–701, 2004

**Y**

**Young adults. See also Adolescents**

Developmental pathology, dopamine, and stress: A model for the age of onset of schizophrenia symptoms, 30(4):875–900, 2004

Study of sexuality-related characteristics in young adults with schizophrenia treated with novel neuroleptics and in a comparison group of young adults, 29(3):559–572, 2003

**Z**

**Ziprasidone**

The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: Schizophrenia trial design and protocol development, 29(1):15–31, 2003



